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ABSTRACT 
                                CHANDRA SUMA MIRYALA 
STRAIN DIFFERENCES IN FLUOXETINE-INDUCED SEXUAL DYSFUNCTION 
DECEMBER 2013 
The present experiments were designed to examine strain differences in sexual 
dysfunction after acute fluoxetine treatment.  Female Fischer and Sprague-Dawley rats 
were used.  Three major experiments were performed.  (1) Strain differences were 
examined in regularly cycling female rats and in ovariectomized rats hormonally primed 
with 0.067 µg/g estradiol benzoate and 3.333 µg/g progesterone following treatment with 
5, 10, 15, 20 or 30 mg/kg fluoxetine. (2) The effects of the 5-HT2 receptor antagonist, 
ketanserin 0.416, 0.5, 1, 2, 5 or 10 mg/kg, were compared in the two strains.  (3) The 
combination of 10 mg/kg fluoxetine and l mg/kg ketanserin was examined. The major 
outcomes of this study were: (i) consistent with prior studies, fluoxetine reduced female 
rat sexual behavior in both hormonally-primed, ovariectomized and in naturally cycling 
rats; (ii) hormonally primed, ovariectomized rats were more sensitive to the lordosis 
inhibiting effects of fluoxetine than the intact, naturally cycling females; (iii) in both 
hormonally-primed and naturally cycling rats, Sprague-Dawley females were less 
sensitive to the lordosis-inhibiting effects of fluoxetine than Fischer females; (iv) a 5-
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HT2A/2C receptor antagonist, ketanserin, reduced lordosis behavior in both strains with a 
slightly greater effect in Sprague-Dawley females, but the difference was modest in 
comparison to the strain differences in response to either fluoxetine, and (v) the 
combination of fluoxetine and ketanserin did not amplify negative effects on lordosis 
behavior relative to the individual drugs alone. From these experiments, it was concluded 
that Fischer female rats are more sensitive than Sprague-Dawley females to the lordosis 
inhibiting effects of fluoxetine and that the 5-HT2 receptor, may not be involved.  
Potential mechanisms responsible for strain differences in the receptor activation are 
discussed. 
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CHAPTER I 
INTRODUCTION 
 
Serotonin (5-HT) is a monoamine neurotransmitter that has been implicated in 
behaviors such as anxiety, depression and eating disorder.  (Berridge et al., 2010; 
D'Souza and Craig, 2010; Lam et al., 2010).  Depression is a common type of mental 
disorder affecting about 10% of the American population (Pratt and Brody, 2008), and 
women are more susceptible and twice more likely to show depression than men 
(Gregorian et al., 2002; Pratt and Brody, 2008).  Although the etiology of depression may 
include dopamine and norepinephrine neurotransmission dysfunction (Dobson et al., 
2003; Fuller and Snoddy, 1993), the major emphasis has been directed towards the 5-HT 
system.   
Monoamine oxidase inhibitors and tricyclics were among the first 
pharmaceuticals that were prescribed for the treatment of depression (Carrasco and Van 
de Kar, 2003; Kehne et al., 1996).  However, with the discovery of selective serotonin 
reuptake inhibitors (SSRIs), such as [±]-N-methyl-γ-[4-(trifluoromethyl)-
phenoxy]benzenepropanamine (fluoxetine) (Prozac®), which showed less severe side 
effects and complications, SSRIs became the prescription of choice (Auger et al., 2001).  
The therapeutic effectiveness of SSRIs led to speculation about the importance of the 
serotonin transporter (SERT) in depression (Owens and Nemeroff, 1994).  While SSRIs 
2 
 
are valuable therapeutic agents, they also produce sexual dysfunction in 30-80% of 
patients (Balon et al., 1993; Clayton, 2003; Michelson et al., 2000; Montejo-Gonzalez et 
al., 1997; Montgomery et al., 2002).  Because there is a 2-3 week delay before patients 
begin to experience remission from symptoms of depression, patients may stop taking 
their medication to avoid these sexual complications (Balon et al., 1993; Rothschild, 
2000).   
Fluoxetine is one of the most widely prescribed of these antidepressants and is 
also among the drugs that produce the greatest amount of sexual dysfunction in human 
females (Clayton et al., 2006; Clayton, 2003).  The sexual dysfunction is thought to result 
from the increase in extracellular 5-HT that results from SSRI blockage of SERT and 
studies in animal models have reinforced this conclusion. 
In female rodents, sexual behavior consists of several aspects defined as 
attractivity, proceptivity and receptivity.  Attractivity refers to the females’ attractiveness 
to the male and includes visual or olfactory cues; proceptivity is the hopping, darting and 
ear wiggling displayed by females that draw attention of a male toward a female; and 
receptivity (or consummatory) behavior is the response elicited by the female’s adoption 
of a posture that facilitates ejaculation by the male (Beach, 1976).  The lordosis posture 
involves arching of the back, elevation of the neck and dorsoflexion of the tail.  In female 
rats, lordosis is quantified as the lordosis quotient, calculated as the ratio of the total 
number of lordosis responses divided by the total number of mounts by the male times 
100 (Beach, 1943) and is used to measure the degree of receptivity of the female.   In 
animal models, compounds which increase 5-HT are known to decrease sexual behavior 
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(Miryala et al., 2012; Mos et al., 1999).  Agents that increase extracellular 5-HT are 
inhibitory to lordosis whereas agents that decrease 5-HT are facilitatory (Mendelson and 
Gorzalka, 1985).  In sub-primate females, sexual behavior is expressed during the 
proestrous stage of the estrous cycle (analogous to the menstrual cycle in human females) 
(Warner, 1927).  Since increased extracellular 5-HT decreases lordosis behavior, it is not 
surprising that fluoxetine reduces sexual behavior.  By blocking the SERT and resulting 
in an increase in extracellular 5-HT (Malagié et al., 1995; Tao et al., 2002), fluoxetine 
leads to increased activation of multiple 5-HT receptors, some of which may contribute to 
the sexual side effects.  There are seven families of 5-HT receptors (5-HT1, 5-HT2,  
5-HT3, 5-HT4, 5-HT5, 5-HT6 and 5-HT7) and, within each family, there are several 
subtypes (Hoyer et al., 2002).  Serotonergic activation of these receptor subtypes elicits 
different responses mediated via different signaling processes (Hoyer et al., 1987). 
Activation of 5-HT1A receptors decreases female sexual behavior (Uphouse et al., 1994), 
while activation of 5-HT2 receptors may increase the behavior (Maswood et al., 1996; 
Wolf et al., 1998).   
Fluoxetine treatment also influences neuroendocrine responses by activation of  
5-HT1A and 5-HT2 receptors, which play a major role in hypothalamic-pituitary-adrenal 
(HPA) function (Bagdy, 1995).   One of the responses to the activation of the HPA 
includes an increase in corticotrophin releasing factor (CRF) from the parvocellular 
neurons of the hypothalamic paraventricular nucleus (PVN) (Jorgensen et al., 1998).  
Since CRF is known to inhibit lordosis behavior (Sirinathsinghji, 1986), it is possible that 
fluoxetine’s HPA activation contributes to its effect on sexual behavior. 
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Regardless of the initial mechanism involved, fluoxetine is well associated with 
sexual dysfunction.  However, all the characteristics of sexual dysfunction (for example, 
low sexual desire, anorgasm) are not observed in a single individual and not all 
individuals are affected (Clayton, 2002; Clayton, 2003; Strohmaier et al., 2011).  Some 
individuals seem resistant to SSRI treatment while others show considerable clinical 
improvement (Rush et al., 2006).  Similarly, in rodent animal models, there is evidence of 
strain differences in the effects of SSRIs (Scholl et al., 2010; Fernandez et al., 2003; 
Yalcin et al., 2008).  Although mechanisms of these sexual side effects are unknown, 
they may involve the SSRI’s effects on the serotonergic system so that individual 
differences in SSRI-induced sexual dysfunction could result from differences in 
functioning of the 5-HT system. 
In spite of evidence for strain differences in the response to SSRIs and other 5-HT 
active compounds (Al Ahmed and Herbert, 2008; David et al., 2003; Sugimoto et al., 
2008), less emphasis has been directed toward the evaluation of the sexual side effects so 
that a limited number of rat strains have been examined.  Fischer females have a higher 
baseline extracellular 5-HT and are thought to be hyper responsive to stress while 
Sprague-Dawley females generally show a low responsivity to stress (Glowa et al., 1992; 
Sternberg et al., 1992).  For example, Rosecrans et al. (Rosecrans et al., 1986) reported 
that 5-HT levels were increased more in Fischer than in Sprague-Dawley rats in response 
to foot shock and that Fischer rats had a higher plasma corticosterone (CORT) than 
Sprague-Dawley rats in response to the stressor (Rosecrans et al., 1986). 
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In a few studies, strains have been compared following treatment with 5-HT 
active drugs. Sprague-Dawley females are more sensitive than Fischer females to lordosis 
inhibition after treatment with a 5-HT1A receptor agonist (Uphouse et al., 2002).  
However, the estrous cycle of Sprague-Dawley females was only moderately interrupted 
by daily treatment with fluoxetine, while the estrous cycle of Fischer females was 
robustly affected (Maswood et al., 2008; Sarkar et al., 2008).  In addition, inhibition of 
lordosis behavior in Fischer females after fluoxetine was inhibited by prior treatment with 
the 5-HT1A receptor antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-
pyridinylcyclohexanecarboxamide (WAY100635), suggesting that the lordosis inhibition 
after fluoxetine in Fischer females is mediated via the 5-HT1A receptor.  The apparently 
contrasting effects of fluoxetine and a 5-HT1A receptor agonist in the two strains may 
challenge the assumption that the fluoxetine-induced decline of lordosis behavior is 
mediated via activation of 5-HT1A receptors.  Since, fluoxetine would lead to an increased 
activation of both 5-HT1A and 5-HT2 receptors, it is possible that the activation of 5-HT2 
receptors protects the Sprague-Dawley females against effects of lordosis inhibition 
mediated through the activation of 5-HT1A receptors (Maswood et al., 1996).  If 5-HT2 
receptors play a greater role in Sprague-Dawley than in Fischer females in the control of 
lordosis behavior, then, in Sprague-Dawley rats, 5-HT2 receptors might compensate for 
the lordosis-inhibiting effects of 5-HT1A receptor activation.  
Alternatively, the apparent contradiction could result from the different models 
used for examination of the effects of fluoxetine and those of the 5-HT1A receptor agonist.  
Estrous cycle differences in Fischer and Sprague-Dawley rats were examined in intact 
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females, while the effects of the 5-HT1A receptor agonist, 8-hydroxy-2(di-n-propylamino-
tetralin (8-OH-DPAT), were examined in ovariectomized, estradiol benzoate (EB) and 
progesterone (P) primed females.  This difference may be important since both EB and P 
influence the number and/or function  of 5-HT1 and 5-HT2 receptors (Sumner et al., 1999; 
Moses et al., 2000), uncouple 5-HT1A receptors from G-proteins (Mize et al., 2003; Lu 
and Bethea, 2002; McQueen et al., 1997), and can influence the effects of 5-HT1A and  
5-HT2 receptor agonists on lordosis behavior (Wilson and Hunter, 1985; Jackson and 
Uphouse, 1998; Sinclair-Worley and Uphouse, 2004).  Therefore, it is important to 
examine the effects of fluoxetine in both intact and ovariectomized models in order to 
further identify the putative strain difference in the response to the SSRI.   
In the following study, an attempt was made to understand the individual 
differences in response to fluoxetine by comparison of two rat strains - Fischer and 
Sprague-Dawley female rats - using the lordosis reflex as a model.  The following 
hypotheses were tested: 
1. Sprague-Dawley females are more sensitive than Fischer females to the 
lordosis inhibiting effects of acute fluoxetine.  This hypothesis was not 
confirmed. 
2. Lordosis inhibition is greater in Sprague-Dawley compared to Fischer females 
after blocking the 5-HT2A/2C receptors with ketanserin.  This hypothesis was 
not confirmed. 
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3. Treatment with fluoxetine and ketanserin will amplify the lordosis inhibition 
in the two strains so that a strain difference will not exist.  This hypothesis 
was not confirmed. 
 From these studies, we have found that Fischer female rats were more sensitive 
than Sprague-Dawley female rats to the lordosis-inhibiting effects of fluoxetine (Miryala 
et al., 2012).  Although, Sprague-Dawley females were more sensitive to the 5-HT1A 
receptor agonist, 8-OH-DPAT, blocking 5-HT2 receptors with the 5-HT2A/C   receptor 
antagonist, ketanserin, showed less strain differences.  Finally, ketanserin and fluoxetine 
were combined and this effect was examined in the two strains.  The combined treatment 
did not amplify the effects of ketanserin and strain differences were not present.  
Collectively, these studies are consistent with evidence that the 2 strains differ in 5-HT 
function and that 5-HT1A, but not 5-HT2 receptors, may differentiate the strains. 
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CHAPTER II 
SPRAGUE-DAWLEY AND FISCHER FEMALE RATS DIFFER IN ACUTE 
EFFECTS OF FLUOXETINE ON SEXUAL BEHAVIOR 
 
A paper published in the Journal of Sexual Medicine, 10(2):350-61 (2013) 
Chandra Suma J. Miryala MS, Cindy Hiegel MA, Lynda Uphouse PhD 
 
ABSTRACT 
Introduction.  The selective serotonin reuptake inhibitor (SSRI), fluoxetine, leads to 
sexual dysfunction in a substantial proportion of women.  In studies with the Fischer 
inbred rat, the 5-HT1A receptor has been implicated in this sexual dysfunction.  Whether 
this association with 5-HT1A receptors holds for other rat strains is not known. 
Aim. The effects of acute fluoxetine on sexual behavior in two strains of rats that differ in 
their response to a 5-HT1A receptor agonist were examined.  Whether the strain difference 
is comparable in naturally cycling and hormonally primed, ovariectomized rats was 
determined. 
Main Outcome Measures.  Lordosis to mount ratios, lordosis quality, and proceptive 
behaviors were quantified.  Sprague-Dawley and Fischer females were compared on each 
of these measures.  The IC50 for inhibition of lordosis behavior was determined. 
Methods.  Proestrous rats and ovariectomized rats, hormonally primed with estradiol 
benzoate and progesterone, were treated with varying doses of fluoxetine.  Sexual 
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behavior was examined before and after treatment with the SSRI.   
Results.  In both the intact and the hormonally-primed, ovariectomized model, Sprague-
Dawley females were less sensitive to the effects of fluoxetine on sexual behavior.  In 
both groups, fluoxetine showed dose-dependency in behavioral inhibition, but a higher 
dose was required for Sprague-Dawley than for Fischer females.  Naturally cycling, 
proestrous rats required a higher dose of fluoxetine than hormonally-primed 
ovariectomized rats to produce significant inhibition of sexual behavior.  Thus, the strain 
difference in the response to fluoxetine does not parallel strain differences in the response 
to a 5-HT1A receptor agonist. 
Conclusions.  Acute treatment with fluoxetine inhibits lordosis behavior in both Fischer 
and Sprague-Dawley females and the strain difference cannot be explained by reported 
strain differences in the response to a 5-HT1A receptor agonist.  Fluoxetine’s inhibition of 
female rat sexual behavior may involve effects of the SSRI in addition to activation of the 
5-HT1A receptor.  
 
Key Words:  Rat strains, female sexual behavior, SSRI, estrogen, progesterone, 
proestrous 
Funding Sources:  NIH HD28419 and TWU REP 
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Introduction 
 After its original marketing in the 1980s, Prozac® (fluoxetine) became one of the 
most frequently prescribed medications for the treatment of depression and other 
disorders of special significance to women [1, 2].  Fluoxetine is a selective serotonin 
reuptake inhibitor (SSRI) thought to exert its therapeutic effect, in part, through blocking 
of the serotonin transporter (SERT) and consequent reduction of serotonin reuptake into 
the nerve terminal [3, 4].  However, in spite of the clinical effectiveness of SSRIs for the 
treatment of mood disorders, the 2 to 3 week delay between onset of treatment and 
clinical effectiveness, coupled with the emergence of sexual side effects, can lead patients 
to discontinue treatment prior to relief from their original clinical symptoms [5-7].   
 Approximately 30-50% of women taking antidepressants experience some kind of 
sexual dysfunction [5] and there is a higher probability of such sexual side effects with 
SSRI treatments leading to suggestions that the sexual dysfunction may involve the 
drugs’ effects on the serotonergic system [5, 8, 9].  However, compared to research on 
male sexual dysfunction, investigation of the mechanisms responsible for SSRI-induced 
female sexual dysfunction has been limited and it is not clear why some females 
experience such sexual side effects while others do not.  From animal models, it is well 
established that manipulations, including fluoxetine, that elevate CNS serotonin have 
inhibitory effects on female rat sexual behavior [10, 11] and activation of the serotonin 
1A (5-HT1A) receptor has been implicated in 5-HT-mediated sexual inhibition [11].  
Activation of the 5-HT1A receptor also contributes to the acute effect of fluoxetine on 
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female rat sexual behavior [12].  However, this association may not hold for the SSRI, 
paroxetine [13], and whether or not this relationship holds across rat strains has not been 
determined.  In fact, the possibility of rat strain differences in fluoxetine’s effect on 
sexual behavior has received little investigation. 
 There is, though, evidence that rat and mouse strains vary in their response to 
several effects of fluoxetine [14-17] and fluoxetine-induced disruption of the female rat’s 
estrous cycle is more prevalent in the Fischer inbred strain than the Sprague-Dawley 
strain [18, 19].  In contrast, Sprague-Dawley females show greater sensitivity than 
Fischer females to the disruptive effects of a 5-HT1A receptor agonist on sexual behavior 
[20].  This is surprising since the Sprague-Dawley strain that is more sensitive to the 5-
HT1A receptor agonist would have been expected to exhibit the greater vulnerability to 
sexual side effects of fluoxetine.  However, it is important to note that effects of a 5-HT1A 
receptor agonist were investigated in hormonally-primed ovariectomized rats while strain 
differences in the effects of fluoxetine on estrous cyclicity were investigated in naturally 
cycling female rats.  Therefore, it is possible that the direction of the strain difference in 
the female’s response to fluoxetine is not the same in the naturally cycling and 
hormonally-primed, ovariectomized model.  The following experiments were designed to 
investigate this possibility.  Portions of these studies were previously reported at the 
Annual Meeting of the Society for Neuroscience [21]. 
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Materials and Methods 
Materials 
 Estradiol benzoate (EB), progesterone (P), sesame seed oil, and the selective 
serotonin reuptake inhibitor, methyl [3-phenyl-3-4-(trifluoromethyl)-phenoxy] propyl] 
ammonium chloride (fluoxetine), were purchased from Sigma-Aldrich Chemical 
Company (St. Louis, MO).  Isoflurane (AErrane®) and suture materials were purchased 
from Butler Schein Animal Health (Dublin, OH).  Food (Rodent Lab Diet 5001) was 
purchased from Lab Animal Supply (Highland Village, Texas).  All other supplies were 
purchased from Fischer Scientific (Houston, TX).  
General Methods 
 All procedures were in accordance with the NIH Guide for the Care and Use of 
Animals in Research and were approved by the Institutional Animal Care and Use 
Committee at Texas Woman's University. 
Animals and Housing Conditions 
Female Fischer and Sprague-Dawley rats were purchased from Charles River 
Laboratories (Wilmington, MA) and housed 2 per cage in standard shoebox caging 
(45.72 × 24.13 × 2.59 cm).  The housing area was maintained at 25 °C and 55% humidity 
with lights on from 12:00 midnight to 12:00 noon.  Food and water were available ad lib.  
Age of the animals varied within experiments but was always matched between Fischer 
and Sprague-Dawley rats and was counterbalanced across treatment conditions. 
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Behavioral Testing Procedures 
On the day of testing, rats were pretested for sexual behavior during the dark 
portion of the light/dark cycle (between 2 and 4 pm) as previously described [22].  
Females were sexually naïve prior to testing and were used only a single time.  Rats were 
placed into the home cage of a sexually active Sprague-Dawley male and behavior was 
monitored until 10 mounts had occurred.  Females were then injected with fluoxetine and 
tested 30 min later for Experiments 1, 2, and 4 or after 5 min for Experiment 3.  Sexual 
receptivity was measured as the lordosis/mount (L/M) ratio (number of lordosis reflexes 
by the female divided by the number of mounts by the male).  Lordosis quality was 
measured on a scale of 1 to 4 as previously described [22] and was computed as the sum 
of individual lordosis quality scores divided by the number of lordosis responses.  Rats 
with only minor arching of the back received a score of 1.0; a standard arch with 
elevation of the head was scored as 3.0; an intermediate arch without head elevation was 
scored as 2.0; and an exaggerated arch with elevation of the front legs was scored as 4.0.  
If the female failed to lordose, no quality score was given.  The number of mounts by the 
male was recorded to assure that females received comparable stimuli.  Proceptivity was 
measured by the presence of hopping and darting behavior.  For L/M ratios, lordosis 
quality, and mounts, data were recorded for the pretest and consecutive intervals after 
fluoxetine.  For proceptivity, the presence or absence of the behavior was recorded and 
females were categorized as either proceptive or not proceptive. 
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Statistical Procedures 
  For Experiments 1 and 2, L/M ratios, lordosis quality scores and number of 
mounts were computed for the pretest and the 15 min test period after fluoxetine.  Data 
were evaluated by repeated measures ANOVA with strain and dose as independent factors 
and before or after fluoxetine as the repeated factor.  Data for experiments 3 and 4 were 
divided into consecutive 5 min (Experiment 4) or 10 min (Experiment 3) intervals and 
were evaluated by repeated measures ANOVA with time relative to the fluoxetine 
injection as the repeated factor and strain as the independent factor.  Proceptivity data 
were compared by Chi-Square or Fisher’s Exact Test procedures.  In the first 2 
experiments, L/M data were subjected to regression on dose for determination of the 
relationship between dose and L/M ratios and for estimation of the IC50.  IC50, the dose 
that leads to 50% inhibition of the maximum effect [23], was defined as an L/M ratio of 
0.5.  SPSS versions 15.0 (for PC) or 17.0 (for Macintosh) were used for data analysis.  
Post-hoc Tukey test comparisons were performed manually and were limited a priori to 
(a) comparisons of data before and after fluoxetine (within treatment) and (b) comparison 
of strains (within dose and test interval) [24].  An alpha level of 0.05 was required for 
rejection of the null hypothesis. 
Specific Methods 
Experiment 1: Intact, Proestrous Rats 
 Fischer and Sprague-Dawley rats were age-matched for the experiment and were 
17-20 weeks of age at the time of testing.   Approximately 2 weeks after their arrival at 
TWU, vaginal cyclicity was monitored daily as previously described [22].  Females 
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showing at least two consecutive 4 to 5 day estrous cycles were tested on the afternoon of 
proestrous.  Proestrus was defined as a relative scarcity of leukocytes and a high density 
of nucleated and cornified cells.  Animals were selected on each test day on the basis of 
their prior vaginal smear history and their vaginal smear on the day of testing with the 
additional requirement that Fischer and Sprague-Dawley females be represented on every 
testing day. 
 On the day of testing, the means ± S.E. body weights of intact Fischer and 
Sprague-Dawley rats were 160.1 ± 1.8 and 264.9 ± 4.6 g, respectively.  On the afternoon 
of proestrous, females were pretested for sexual behavior and immediately injected 
intraperitoneally (ip) with 10, 15, 20 or 30 mg/kg of fluoxetine hydrochloride.  Thirty 
min later, females were again tested in the home cage of a sexually active male.  Testing 
continued for 15 consecutive min.  Data were compared for the pretest (before fluoxetine) 
and a 15 min test period 30 through 45 min after fluoxetine. 
Experiment 2:  Hormonally Primed, Ovariectomized Rats 
 Approximately two weeks after their arrival, females were ovariectomized under 
AErrane® anesthesia as previously described [22].  Ten to 14 days later, rats were 
hormonally primed with estradiol benzoate (EB) followed 48 hr later with progesterone 
(P).  Because Fischer and Sprague-Dawley females differ in body weight, hormones were 
administered by body weight (0.067 µg /g EB and 3.333 µg/g  P) and were the same 
doses as previously used in the strain comparison with a 5-HT1A receptor agonist [20].  
These doses are roughly equivalent to 10 µg EB and 500 µg P for a 150 g Fischer female.  
EB and P were dissolved in sesame seed oil and administered subcutaneously (sc) in a 
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volume of 0.1 ml/150 g body weight.  On the day of testing, Fischer and Sprague-Dawley 
females were 15-19 weeks of age and weighed 168.8 ± 1.4 and 276.2 ± 3.4 g, 
respectively. 
 Immediately following the pretest, females were injected with 5, 10, 15 or 20 
mg/kg fluoxetine.  A lower dose range was chosen for ovariectomized females because of 
an expectation that the ovariectomized rats would be more sensitive to the effects of 
fluoxetine.  This expectation was derived from prior work demonstrating that sexual 
behavior of naturally cycling females is more resistant to disruption by both chemical and 
experimental factors than is that of hormonally-primed ovariectomized rats [11, 20, 25].  
Although exogenous hormonal treatment is effective in priming for sexual behavior, it 
does not replicate the endogenous pattern of hormonal secretion that is probably optimal 
for maintenance of reproductive activity.  Thirty min after fluoxetine, rats were retested 
for sexual behavior as in Experiment 1.  Data were compared before and for 15 
consecutive min of testing 30 through 45 min after fluoxetine. 
Experiment 3:  Rapid Effects of Fluoxetine in Hormonally Primed, Ovariectomized Rats 
 Females were ovariectomized and hormonally primed as for Experiment 2.  Rats 
fell into two different age groups (14-15 weeks or 20 weeks) and all treatment conditions 
were represented in both age groups.  Fischer and Sprague-Dawley females weighed 
160.2 ± 3.07 and 257.2 ± 7.94, respectively, on the day of testing.  After the pretest for 
sexual behavior, females were injected with 15 mg/kg fluoxetine.  Five min later, rats 
were tested for sexual behavior for 40 consecutive min (to allow overlap with rats tested 
30 min after fluoxetine).  Data were computed for the pretest and for the 4 continuous 10 
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intervals after initiation of testing.   Sexual behavior and motor disturbances were 
monitored.  Females were judged to exhibit motor disturbance when they showed 
immobility, disordered gait, or difficulty with ambulation.  L/M ratios and lordosis 
quality were compared by repeated measures ANOVA with test interval as the repeated 
factor.  Motor disturbance was evaluated by Chi-Square procedures. 
Experiment 4: Effect of Hormonal Priming per Rat 
 In Experiments 2 and 3, hormonal priming was based on body weight so that the 
larger Sprague-Dawley females received higher absolute amounts of hormones.  Both 
estradiol and progesterone can influence the serotonergic system [26] and progesterone 
can reduce effects of fluoxetine on lordosis behavior [12].  Therefore, in the final study, 
rats were treated as described for Experiment 2 but doses of 10 µg EB and 500 µg P per 
rat were given to both strains.  EB and P were dissolved in sesame seed oil and 
administered subcutaneously (sc) in a volume of 0.1 ml/rat.  At the time of testing, rats 
were 18-20 weeks of age and weighed 166.8 ± 2.23 and 280.1 ± 5.47, respectively, for 
Fischer and Sprague-Dawley females.  After the pretest for sexual behavior, rats were 
injected with 15 mg/kg fluoxetine.  Behavioral testing was initiated 30 min after 
progesterone and continued for 15 consecutive min.  Data were computed for the pretest 
and 3 continuous 5-min intervals after fluoxetine and were analyzed by repeated 
measures ANOVA as for Experiment 3.   
Outcome Measures 
 Lordosis to mount ratios, lordosis quality, and proceptive behaviors were quantified.  
Hormonally-primed and naturally-cycling Sprague-Dawley and Fischer females were 
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compared on each of these measures.   The IC50 for inhibition of lordosis behavior was 
determined. 
Results 
Experiment 1: Intact, Proestrous Females 
 In intact, proestrous females, there was a significant main effect of strain (F1, 40 = 
10.71, p ≤ 0.002) and dose on L/M ratios after fluoxetine (Figure 2.1; F3, 40 = 6.77, p ≤ 
0.001).  Strains did not differ in L/M ratios before fluoxetine.  L/M ratios declined after 
fluoxetine leading to a significant effect of time (e.g. before or after fluoxetine) that was 
due primarily to effects in Fischer females (F1, 40 = 45.68, p ≤ 0.001).  There was a 
significant time by strain interaction (F1,40 = 11.55, p ≤ 0.002) as well as a significant 
time by dose interaction (F3,40 = 7.23, p ≤ 0.001).   L/M ratios of Fischer rats were 
significantly different from their pretest after 15, 20 and 30 mg/kg fluoxetine (q40, 4, 
respectively, = 4.03, 6.59 and 8.99, p ≤ 0.05).  In contrast, L/M ratios of Sprague-Dawley 
females differed from their pretest only after 30 mg/kg (q40, 4 = 4.64, p ≤ 0.05).  L/M 
ratios of Fischer rats were significantly lower than those of Sprague-Dawley rats at the 20 
and 30 mg/kg doses (respectively, q40, 4 = 5.50 and 4.35, p ≤ 0.05).   
 There was a significant linear relationship between dose and L/M ratios for both 
strains (for Fischer and Sprague-Dawley, respectively, r = 0.78 and 0.52, p ≤ 0.001).   
The IC50 for Fischer and Sprague-Dawley females, respectively, was 26.0 and 64.4 
mg/kg. 
 Females that failed to show lordosis behavior were omitted from the analysis for 
lordosis quality.  For the remaining rats, fluoxetine had relatively minor effects (data not 
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shown).  There was a significant effect of dose (F3,38 = 3.43, p ≤ 0.026) and an interaction 
between strain and dose (F3,38 = 7.14, p ≤ 0.001) due to a lower lordosis quality in Fischer 
females after 15 mg/kg fluoxetine and in Sprague-Dawley females after 30 mg/kg; but 
even after 30 mg/kg, Fischer and Sprague-Dawley rats, respectively, showed relatively 
high lordosis quality (average scores of 2.79 ± 0.09 and 2.27 ± 0.20). 
 Prior to injection with fluoxetine, 84% of Fischer and 100% of Sprague-Dawley 
females showed proceptive (hopping and darting) behavior.  In both strains, fluoxetine 
dose-dependently reduced proceptivity (Chi Square values for Fischer and Sprague-
Dawley, respectively, were 28.72 and 40.62, df = 4, p ≤ 0.001; see Figure 2.2).  However, 
Fischer females were affected at a lower dose than Sprague-Dawley females.  Fischer 
females were significantly different from their pretest after 20 and 30 mg/kg fluoxetine 
while Sprague-Dawley females differed only after 30 mg/kg.  As a consequence, the 
strains differed significantly only at 20 mg/kg fluoxetine (Chi Square = 7.63, df = 1, p ≤ 
0.006). 
 The strain difference in lordosis behavior was not due to differential mounting by 
the males (p > 0.05).  The mean ± S.E. number of mounts during the 15 min after 
injection for Fischer and Sprague-Dawley rats, respectively, for 10, 15, 20 and 30 mg/kg 
fluoxetine, were: 14.83 ± 2.52, 19.28 ± 3.03, 24.3 ± 3.91, 18.5 ± 3.62 and 15.16 ± 1.51, 
17.16 ± 2.27, 21.0 ± 2.9, 17.66 ± 4.57. 
Experiment 2:  Hormonally Primed, Ovariectomized Females 
  Strain differences in hormonally-primed, ovariectomized rats were similar to 
those of intact females with Fischer females showing the greater decline in L/M ratios 
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after fluoxetine (ANOVA for strain, F1, 54 = 5.27, p ≤ 0.026; see Figure 2.3).  There was 
also a significant main effect of dose (F3, 54 = 9.39, p ≤ 0.001) and a strain by dose 
interaction (F3, 54 = 3.08, p ≤ 0.035).  The time-dependent decline (before versus after 
fluoxetine) in L/M ratios (F3, 54 = 94.59, p ≤ 0.001) interacted significantly with both 
strain (F1, 54 = 14.65, p ≤ 0.001) and dose (F3, 5 = 14.11, p ≤ 0.001), and there was a 
significant 3-way interaction (F3, 54 = 2.82, p ≤ 0.048).  L/M ratios of Fischer females 
were significantly different from their pretest after 10, 15 and 20 mg/kg fluoxetine (all 
q54,4 ≥ 4.97, p ≤ 0.05) while L/M ratios of Sprague-Dawley females differed from their 
pretest only after 20 mg/kg (q54,4 = 5.39, p ≤ 0.05).  L/M ratios of the two strains differed 
significantly after 15 and 20 mg/kg (respectively, q54,4 = 4.15 and 8.16, p ≤ 0.05). 
  As for intact females, there were significant linear regressions between dose and 
L/M ratios (respectively, for Fischer and Sprague-Dawley rats, r = 0.82 and 0.56, p ≤ 
0.001).  The IC50 was 16.93 and 39.5 mg/kg for Fischer and Sprague-Dawley females, 
respectively.  
  Females that did not show lordosis after fluoxetine were omitted from the data 
analysis.  For the remaining rats, lordosis quality decreased after fluoxetine (ANOVA for 
pre versus post, F1, 54 = 49.58, p ≤ 0.001; data not shown) and there was a significant 
interaction between time and dose of fluoxetine (F3, 54 = 4.57, p ≤ 0.006).  No other 
effects were significant.   Lordosis quality after 20 mg/kg fluoxetine ranged from a high 
of 2.4 ± 0.198 to a low of 2.1 ± 0.75 in Fischer and Sprague-Dawley rats, respectively. 
 Before injection with fluoxetine, 65.62% of Fischer females and 80% of Sprague-
Dawley females showed proceptive behavior which declined after fluoxetine (Chi Square 
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= 9.44 and 12.65, respectively, for Fischer and Sprague-Dawley females, df = 4, p ≤ 0.05; 
see Figure 2.4).  Proceptivity of Fischer females was lower than their pretest at every 
dose of fluoxetine but, because of relatively low proceptivity in the pretest, showed a 
significant difference only after 15 and 20 mg/kg of fluoxetine (Fisher’s Exact Test, p ≤ 
0.03).  Proceptivity of Sprague-Dawley females declined at 10, 15 and 20 mg/kg 
fluoxetine but were only significantly different from their pretest at 10 mg/kg (Fischer’s 
Exact Test, p ≤ 0.014).  Since proceptivity declined in both strains, only after 5 mg/kg 
was there a significant strain difference in proceptivity (Chi Square = 5.33, df = 1, p ≤ 
0.02) and this primarily reflected the 100% incidence of proceptivity in Sprague-Dawley 
females at this dose. 
 Strain differences in lordosis behavior did not result from differences in number 
of mounts from the male. The mean ± S.E. number of mounts during the 15 min after 
injection for Fischer and Sprague-Dawley rats, respectively, for 5, 10, 15 and 20 mg/kg 
fluoxetine, were 27.25 ± 2.84, 16.62 ± 1.51, 20.44 ± 1.56, 27.25 ± 4.33 and 19.37 ± 2.18, 
25.57 ± 4.11, 23.28 ± 2.66, 18.75 ± 2.45.  None of the main effects were significant but 
there was a significant strain by dose interaction (F3, 54= 3.58 ≤ 0.020) due to slightly 
fewer mounts of Sprague-Dawley females at 5 mg/kg and slightly more mounts at 10 
mg/kg.  
 Ovariectomized rats appeared to be more sensitive than intact rats to the lordosis-
inhibiting effects of fluoxetine.  Therefore, a post facto comparison of the two data sets 
was performed on the L/M ratios after injection with 10, 15 or 20 mg/kg fluoxetine (the 
doses present in both Experiments 1 and 2).  There was the expected main effect of strain 
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(F1,70 = 19.98,  ≤ 0.001), dose (F2,70 = 8.32, p ≤ 0.001) and their interaction (F2,70= 5.03, p 
≤ 0.009).  As anticipated from the dose response analyses for Experiments 1 and 2, type 
of animal (e.g. ovariectomized or intact) was also a significant factor (F1,70 = 14.86, 
p ≤0.001) 
Experiment 3: Rapid Effects of Fluoxetine in Hormonally Primed, Ovariectomized Rats 
 The next experiment was designed to determine if strain differences examined 30 
min after fluoxetine resulted from different rates of recovery from the immediate effects 
of fluoxetine on motor function.  Continuous behavioral monitoring began 5 min after 
injection with 15 mg/kg fluoxetine.  As expected, females showed motor disturbances, 
characterized primarily by immobility, early after treatment (see Table 2.1).  
Surprisingly, a greater proportion of Sprague-Dawley females showed evidence of motor 
disturbance than did Fischer females; but this difference was not significant (Chi Square, 
p > 0.05).  Probably because of this immobility (especially 10 to 20 min after injection), 
males expressed low interest in the females so that mounting did not occur for every 
female in every 5-min interval.  In particular, 4 Sprague-Dawley and 1 Fischer female 
had no mounts during at least one 5-min test interval after treatment with fluoxetine so 
the data were collapsed into 10-min intervals for analysis.  
 The rapid effects of fluoxetine on L/M ratios are shown in Figure 2.5.  Compared 
to Experiment 2 when testing was delayed for 30 min after injection (Figure 2.3), 
Sprague-Dawley females had lower L/M ratios when testing began 5 min after fluoxetine.  
Both strains, therefore, showed robust declines in L/M ratios within the first 15-20 min 
after fluoxetine, and the main effect of strain was not significant (F1, 17 = 0.44, p ≤ 0.05).  
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There was a significant effect of time (F4, 68 = 24.44, p ≤ 0.001) but not a significant 
interaction between time and strain (F4, 68 = 0.48, p ≤ 0.05).  In contrast to behavior tested 
30 min after fluoxetine, with the immediate initiation of testing, L/M ratios of both strains 
were significantly different from the pretest at every test interval (all q5.68 ≥ 3.97, p ≤ 
0.05).   For both strains, L/M ratios gradually increased after the early nadir to reach L/M 
ratios at the end of testing that were similar in Fischer females to those seen in 
Experiment 2 but lower in Sprague-Dawley females.   
 For lordosis quality, there were several missing intervals due to L/M ratios of zero 
so data were evaluated by repeated measures ANOVA with lordosis quality before and 
after fluoxetine as the repeated factors.  There was a significant decline in lordosis quality 
after injection (ANOVA for time F1, 21 = 84.76, p ≤ 0.001) but neither the strain (F1, 21 = 
0.46, p > 0.05) nor the strain by time interaction (F1, 21 = 1.25, p > 0.05) were significant.  
The means ± S.E. lordosis quality for Fischer females before and after fluoxetine, 
respectively, were 2.9 ± 0.05 and 1.69 ± 0.17; for Sprague-Dawley, lordosis quality 
before and after fluoxetine were 2.7 ± 0.05 and 1.7 ± 0.18, respectively. 
 Proceptivity was reduced by the SSRI and Fischer rats were more severely 
affected and for a longer time interval than Sprague-Dawley females (Table 2.1) [strain 
differences were present at the 20-25 min and 40-45 min intervals (Fischer’s Exact test, p 
< 0.05)].  When the relationship between immobility and proceptivity was examined, the 
two variables were inversely correlated in Sprague-Dawley females at the 10 to 15, 20 to 
25, and 40 to 45 min intervals (respectively, r = -0.74, -0.69, and -0.67; p ≤ 0.05).  For 
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Fischer females, a significant correlation was present only at the 10 to 15 min interval (r 
= -0.47, p ≤ 0.05).  
Experiment 4:  Effects of Hormonal Priming per Rat 
 In a final experiment, ovariectomized Fischer and Sprague-Dawley females were 
primed with 10 µg EB and 500 µg P per rat to determine if strain differences resulted 
from the greater amount of hormones received by Sprague-Dawley females when 
hormones had been administered relative to body weight.  As shown in Figure 2.6, strain 
differences were still evident with Sprague-Dawley females being less sensitive to 
fluoxetine than Fischer females. However, in contrast to Experiment 2, the strain 
difference was present only early during testing. 
 There was a significant effect of time (F3,60 = 11.48, p ≤ 0.001) and a significant 
strain by time interaction (F3,60 = 4.76, p ≤ 0.005) for L/M ratios.  Ratios for Fischer 
females were significantly different from their pretest during the 30-35 and 35-40 min 
intervals after fluoxetine (q60,8 ≥ 4.36, p ≤ 0.05) while ratios for Sprague-Dawley females 
were never significantly different from their pretest.  The apparent differences between 
Experiment 2 and Experiment 4 resulted from a slightly lower L/M ratio of Sprague-
Dawley females in Experiment 4 and the unusually high L/M ratio of Fischer females 
during the last test interval.   
 For lordosis quality, 1 Sprague-Dawley and 4 Fischer females had L/M of zero 
during at least one test interval.  For remaining rats, there was a decrease in lordosis 
quality (data not shown) after fluoxetine (F3,45 = 2.87, p ≤ 0.046) but no other effects 
were significant.  Similarly, the only significant effect for mounts was for time (F3,66 = 
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7.96, p ≤ 0.001).  The average numbers of mounts per 5 min test interval after fluoxetine 
were 5.44 ± 0.96 and 7.5 ± 0.96 for Fischer and Sprague-Dawley females, respectively. 
Discussion 
 Three major observations were made in these studies:  (1) both lordosis behavior 
and proceptivity were reduced by fluoxetine; (2) hormonally-primed, ovariectomized 
females were more sensitive to the antidepressant than naturally cycling, intact females; 
and (3) both hormonally-primed, ovariectomized and intact Sprague-Dawley females 
were less sensitive to the disruptive effects of fluoxetine on sexual behavior than were 
Fischer females.  These studies were originally initiated because Sprague-Dawley 
females show greater sensitivity to the lordosis-inhibiting effects of a 5-HT1A receptor 
agonist [20] and 5-HT1A receptors have been implicated in fluoxetine’s antidepressant 
actions [27, 28] and in the SSRI’s reduction of female rat sexual behavior [12].  It was, 
therefore, expected that Sprague-Dawley females might also be more sensitive to the 
effects of fluoxetine on sexual behavior.  This clearly was not the case and challenges the 
role of 5-HT1A receptors in fluoxetine’s effect on sexual behavior.   
 However, relative to Sprague-Dawley or some other rat strains, Fischer rats are 
reported to have more SERT mRNA in the dorsal raphe nucleus [29].  If this translates 
into greater SERT activity in dorsal raphe of Fischer females, then fluoxetine would be 
expected to (a) increase extracellular 5-HT to a lesser extent in the vicinity of the dorsal 
raphe and (b) lead to a lesser activation of somatodendritic 5-HT1A autoreceptors that 
function to reduce firing of 5-HT neurons.  Consequently, extracellular 5-HT in brain 
areas such as the mediobasal hypothalamus that are important in the control of female 
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sexual behavior could be elevated more by fluoxetine in Fischer than in Sprague-Dawley 
females.  In addition, because of a putative hyper functional 5-HT system in Fischer rats 
[29, 30], a lower dose of fluoxetine might be expected to reduce lordosis behavior.  Such 
differences in SERT activity might account for the reversal of strain difference profiles 
found here after fluoxetine compared to that previously reported for a 5-HT1A receptor 
agonist.   
 This possibility is even more interesting since Sprague-Dawley females appeared 
to have greater motor disturbance than Fischer females.  Serotonin’s effect on several 
indices of motor function is thought to result from effects on the descending 5-HT system 
[31, 32] while sexual behavioral effects may result from effects on ascending 5-HT 
systems [11].  A potential dissociation between fluoxetine effects on sexual behavior and 
motor function was seen in the current study where Sprague-Dawley females showed 
more motor effects than Fischer females. 
 The hyper functional HPA axis of Fischer rats could also contribute to the strain 
difference in the response to fluoxetine.  Relative to several other rat strains, Fischer rats 
are thought to be more HPA responsive [30, 33], have a higher [34] and longer duration 
[35] corticosterone response to stress, and are regarded to be a highly emotionally 
reactive strain [36].  Acute treatment with fluoxetine is associated with increased 
activation of the hypothalamic-pituitary-adrenal axis [37] and adrenal corticosterone has 
been implicated in some effects of fluoxetine [15].  Therefore, fluoxetine’s acute 
anxiogenic action may be more disruptive for Fischer than for Sprague-Dawley females. 
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 The observation that ovariectomized females were more sensitive than intact 
females to the effects of fluoxetine is not surprising since the endogenous sequence of 
hormonal priming is probably optimal for both facilitation of sexual behavior and for 
resistance to its disruption.  Relative to other stages of the estrous cycle, proestrous 
females show a blunted response to SSRIs as measured either by micro dialysis of the 
mediobasal hypothalamus [38] or by in vivo chronoamperometry of the hippocampus 
[39].  In the naturally cycling female, both estrogen and progesterone likely contribute to 
the smaller response to SSRIs by their modulation of SERT activity and/or by modulation 
of serotonin receptor number and/or function [26].  Although such hormonal modulation 
also occurs in ovariectomized, hormonally-primed females, the temporal characteristics 
of the priming mimic but do not replicate that of the naturally cycling animal. 
 In ovariectomized rats, both EB and P alter the behavioral and neurochemical 
responses to fluoxetine [40-43].  In EB-primed ovariectomized Fischer rats, P was 
reported to attenuate the lordosis-inhibiting effects of fluoxetine by shifting fluoxetine’s 
dose response curve to the right [12] and fluoxetine’s reduction of sexual behavior can be 
reduced by the progesterone metabolite, allopregnanolone [44].  Therefore, potential 
strain differences in gonadal steroids could influence the strain-dependent response to 
fluoxetine.  It is important to note that Fischer and Sprague-Dawley females were age-
matched for these experiments so that Sprague-Dawley females weighed approximately 
1.5 times that of Fischer females.  In Experiments 2 and 3, with ovariectomized rats, both 
EB and P were administered per body weight so that Sprague-Dawley females received 
greater absolute amounts of the hormones than their Fischer counterparts.  It is possible 
28 
 
that the greater amount of hormones contributed to the lower effect of fluoxetine in 
Sprague-Dawley rats.  Indirect evidence for hormonal modulation of SERT activity has 
been reported for both Fischer [38] and Sprague-Dawley [39] females and effects of 
gonadal hormones on serotonin receptor function have been reported for both strains [45, 
46].  In the current experiment, when both strains received the same dose of hormones 
(10 µg/rat EB and 500 µg/rat P), the strain difference was present but was not persistent 
throughout the 15 min testing.  The absence of a strain difference in the latter parts of the 
15 min testing was a reflection of lower L/M ratios in Sprague-Dawley females given the 
lower concentrations of hormonal priming while L/M ratios of Fischer females were 
slightly higher than in prior experiments.  Although this outcome could evidence a slight 
protective effect of the higher hormonal priming in Sprague-Dawley females, the fact that 
both the naturally-cycling and hormonally-primed, ovariectomized Fischer rats showed 
heightened sensitivity to fluoxetine makes it unlikely that differential responses to 
exogenous hormonal priming is the only explanation for the strain difference.  In the few 
studies in which endogenous levels of hormones have been compared in Fischer and 
Sprague-Dawley females, there has been little evidence of consistent strain differences in 
plasma levels of both estradiol and progesterone [47, 48]. Nevertheless, such 
consideration deserves further examination since there is some evidence that chronic 
treatment with SSRIs may reduce serum levels of gonadal hormones [49, 50]. 
 Estradiol is essential for facilitation of lordosis behavior while progesterone is not 
required but is more important for the occurrence of proceptive behavior [51].  The 
hormonal priming used in the present study is sufficient to elicit high levels of lordosis 
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responding in Fischer females but is not adequate for facilitation of proceptivity [22].   
The fact that both lordosis behavior and proceptivity were reduced by fluoxetine 
challenges a simple hormonal explanation for the strain difference seen in the current 
study.  Nevertheless, we cannot rule out the possibility that the strains differ in the degree 
to which the gonadal hormones modulate their serotonergic and/or other neuronal system.  
 Regardless of the ultimate explanation for the strain differences, the current 
findings illustrate the potential importance of genetic differences in the vulnerability for 
development of SSRI-induced sexual dysfunction.  It is increasingly recognized that 
genetic differences contribute to both the vulnerability for development of mood 
disorders and for the therapeutic efficacy of SSRIs [52-54].   Similarly, differences in the 
behavioral and neurochemical responses to SSRIs have been reported for a variety of 
mouse and rat strains [55, 56].  Less attention has been focused on the possibility of 
genetic contributions for vulnerability to SSRI-induced sexual side effects.  Although 
some 30-50% of females that are treated with SSRIs may develop some form of sexual 
dysfunction, the remaining 50-70% does not.  The factors responsible for resistance to 
these sexual side effects are not known.  However, Bishop and colleagues have described 
evidence that genetic polymorphisms in the promoter regions of the 5-HT2A receptor gene 
or in the SERT gene may influence vulnerability to SSRI-associated sexual dysfunction 
[57, 58] but not all reports agree [59].  Other investigators have implicated individual 
differences in the effect of SSRIs on the P450 2D6 isoenzyme leading to accumulation of 
higher concentrations of the drugs [60].  Clearly, the ideal would be to differentiate those 
factors that are required for the therapeutic efficacy of SSRIs from those which lead to 
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sexual side effects.  The differential vulnerability of Fischer and Sprague-Dawley 
females to SSRI-induced inhibition of female sexual behavior could, therefore, be 
valuable in identifying these factors. 
Conclusions 
Fischer inbred female rats are more sensitive than Sprague-Dawley females to the acute 
sexual side effects of fluoxetine.  This difference appears to be independent of gonadal 
hormones. 
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Figure 2.1 Fluoxetine dose-dependently decreased L/M ratios in intact rats. 
Proestrous Fischer (F) and Sprague-Dawley (S-D) females were pretested for sexual 
behavior and then injected ip with 10, 15, 20 or 30 mg/kg fluoxetine.  Thirty min later, 
sexual behavior was again monitored for 15 consecutive min.  Data are the mean ± S.E. 
lordosis/mount (L/M) ratios before (PRE) and for the 15 min after fluoxetine.  Ns for 
Fischer rats at 10, 15, 20 and 30 mg/kg fluoxetine, respectively, were 6, 7, 6 and 6; Ns, 
respectively, for Sprague-Dawley rats were 6, 6, 5, and 6. * indicates significant 
difference between Fischer and Sprague-Dawley rats within dose of fluoxetine; † 
indicates significant difference from the pretest, within strain.  
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Figure 2.2 Dose-dependent effects of fluoxetine on proceptivity of intact rats. 
Data are for the same rats shown in Figures 2.1 and are the percentage of rats that showed 
evidence of proceptivity before (PRE) and after fluoxetine treatment. * indicates 
significant strain differences within dose of fluoxetine.  † indicates significant difference 
from the pretest, within strain.  
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Figure 2.3 Fluoxetine dose-dependently decreased L/M ratios in hormonally primed, 
ovariectomized rats.  Ovariectomized rats, hormonally primed with 0.067 µg EB/g body 
weight and 3.33 µg P/g body weight were pretested for sexual behavior 4 to 6 hr after P.  
Rats were then injected with 5, 10, 15, or 20 mg/kg of fluoxetine.  Thirty minutes later, 
rats were again tested for 15 consecutive min.  Data are the mean ± SE L/M ratios for the 
pretest (PRE) and 15 min after fluoxetine.  The Ns for Fischer (F) and Sprague-Dawley 
(S-D) rats for 5, 10, 15 and 20 mg/kg fluoxetine, respectively, were 8, 8, 9 and 7 and 8, 7, 
7 and 8.  * indicates significant strain differences within dose of fluoxetine.  † indicates 
significant difference from the pretest, within strain.  
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Figure 2.4 Dose-dependent effects of fluoxetine on proceptivity in hormonally primed, 
ovariectomized rats.  Data are for the same rats shown in Figure 2.3 and are the 
percentage of rats that showed evidence of proceptivity before (PRE) and after fluoxetine 
treatment.  * indicates significant strain differences within dose of fluoxetine.  † indicates 
significant difference from the pretest, within strain.  
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Figure 2.5 Rapid effects of fluoxetine on lordosis behavior. 
Ovariectomized rats, hormonally primed with 0.067 µg EB/g body weight and 3.33 µg 
P/g body weight were pretested for sexual behavior 4 to 6 hr after P.   Rats were then 
injected with 15 mg/kg of fluoxetine and 5 min later were tested for 40 consecutive min.  
Data are the mean ± SE L/M ratios for the pretest (PRE) and consecutive 10-min 
intervals initiated 5 min after fluoxetine injection.  The Ns for Fischer (F) and Sprague-
Dawley (S-D) rats respectively were 12 and 7.  † indicates significant difference from the 
pretest, within strain.  
 
 
44 
 
 
Figure 2.6 Strain differences when given constant hormonal priming.  
Ovariectomized rats, hormonally primed with 10 µg EB and 500 µg P per rat were 
pretested for sexual behavior 4 to 6 hr after P.   Rats were then injected with 15 mg/kg of 
fluoxetine and 30 min later were tested for 15 consecutive min.  Data are the mean ± SE 
L/M ratios for the pretest (PRE) and consecutive 5-min intervals 30 min after fluoxetine 
injection.  The Ns for Fischer (F) and Sprague-Dawley (S-D) rats respectively were 11 
and 11.  * indicates significant strain differences within dose of fluoxetine.  † indicates 
significant difference from the pretest, within strain.  
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Table 2.1 Early effects of fluoxetine on the percentage of females showing motor 
disturbance and proceptivity 
 PRETEST 10-15 MIN 20-25 MIN 30-35 MIN 40-45 MIN 
MOTOR  
DISTURBANCE 
     
Fischer 0 38.4 30.7 15.3 7.6 
Sprague-Dawley 0 63.6 45.5 36.4 27.3 
PROCEPTIVITY      
Fischer 76.9 18.18 0* 23.07 8.3* 
Sprague-Dawley 100 20 36.36 45.45 54.45 
 
*Indicates significant difference between strains, within time interval. 
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CHAPTER III 
COMPARISON OF FEMALE FISCHER AND SPRAGUE-DAWLEY RATS 
IN THE RESPONSE TO KETANSERIN 
A Paper Submitted For Publication in the Journal of Pharmacology Biochemistry and 
Behavior (2013) 
Chandra Suma Johnson Miryala, Cindy Hiegel, and Lynda Uphouse 
 
ABSTRACT 
 The effect of the 5-HT2A/2C receptor antagonist, ketanserin, on lordosis behavior 
was examined in hormonally primed, ovariectomized Fischer and Sprague-Dawley 
females.  Rats were primed with 0.067 µg/g body weight estradiol benzoate and 3.33 
µg/g body weight progesterone.  After a pretest for sexual behavior, rats were injected 
with 0.416 to 10 mg/kg ketanserin.  In both strains, lordosis behavior, lordosis quality, 
and proceptivity were significantly reduced by ketanserin.  There was modest evidence of 
a strain difference with Sprague-Dawley females slightly more sensitive to ketanserin.   
In a second experiment, the effects of 10 mg/kg fluoxetine, 1 mg/kg ketanserin, and their 
combination were examined to determine if the two drugs would have additive effects on 
sexual behavior.  There was no evidence that the drugs were additive in their effect and 
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the strains did not differ in their response to the combined treatment.  These findings are 
discussed in relation to prior evidence for strain differences in the sexual behavioral 
response to fluoxetine and to a receptor agonist acting preferentially at 5-HT1A receptors. 
 
Key Words:  Rat strains, ovariectomized, fluoxetine, 5-HT2 receptors, lordosis behavior, 
proceptivity 
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1. Introduction 
 A role for serotonin (5-HT) in the modulation of female rat sexual behavior is 
widely recognized (Mendelson and Gorzalka, 1990; Uphouse and Guptarak, 2010).   A 
variety of drugs that increase extracellular 5-HT inhibit lordosis behavior but, depending 
on the receptor subtype activated, 5-HT receptor agonists can either inhibit or facilitate 
the behavior  (Gonzalez et al., 1997; Hunter et al., 1985; Uphouse et al., 1996; Uphouse 
and Caldarola-Pastuszka, 1993; Wolf et al., 1998).  The best characterized such agonists 
are the 5-HT1A receptor agonists which rapidly inhibit lordosis behavior (Mendelson, 
1992; Uphouse, 2000).  As a result, it has been generally assumed that increased 
extracellular 5-HT reduces lordosis behavior by activation of 5-HT1A receptors.  In 
contrast, agonists that act primarily on 5-HT2 or 5-HT3 receptors facilitate lordosis 
behavior in female rats with relatively low sexual receptivity (Mendelson and Gorzalka, 
1985; Wolf et al., 1999; Wolf et al., 1998).  A potentially beneficial effect of 5-HT2 and 
5-HT3 receptors is inferred from observations that 5-HT2 and 5-HT3 receptor agonists 
protect against the lordosis-inhibiting effects of 5-HT1A receptor agonists (Maswood et 
al., 1998; Uphouse et al., 1994) and that 5-HT2 and 5-HT3 receptor antagonists inhibit 
lordosis behavior (Gonzalez et al., 1997; Maswood et al., 1997).  Therefore, drugs which 
lead to generalized increases in extracellular 5-HT could disrupt the balance between 
activation of 5-HT receptors that inhibit and those that facilitate lordosis behavior.  The 
relevance of such a disruption is evidenced by the large number of human females who 
show sexual dysfunction following treatment with selective serotonin reuptake inhibitors 
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(SSRIs), such as fluoxetine (Clayton et al., 2006; Clayton, 2002; Gelenberg et al., 2000; 
Gregorian et al., 2002). 
 SSRIs block the serotonin transporter (SERT) and thereby lead to an increase in 
extracellular 5-HT and enhanced activation of all 5-HT receptors  (Fuller et al., 1991; 
Gobert et al., 1997; Perry and Fuller, 1992, 1993; Sghendo and Mifsud, 2011; Tao et al., 
2002; Tavoulari et al., 2009), but it is the activation of 5-HT1A receptors that has been 
postulated to account for the lordosis inhibition that follows treatment with fluoxetine 
(Guptarak et al., 2010).  However, not all rat strains show comparable vulnerability to the 
lordosis-inhibiting effects of either fluoxetine or a 5-HT1A receptor agonist (Miryala et 
al., 2013; Uphouse et al., 2002).  For example, Fischer rats have a higher baseline level of 
5-HT than Sprague-Dawley rats (Rosecrans et al., 1986), show an accentuated 5-HT 
response to stress (Dhabhar et al., 1993; Kosten and Ambrosio, 2002; Rosecrans et al., 
1986), and are more responsive to the lordosis-inhibiting effects of fluoxetine than are 
Sprague-Dawley females (Maswood et al., 2008; Miryala et al., 2013; Uphouse et al., 
2006).  However, Fischer females are less responsive than Sprague-Dawley females to 
the lordosis-inhibiting effects of a 5-HT1A receptor agonist (Uphouse et al., 2002) 
suggesting that strain differences in the lordosis response to fluoxetine may include 
additional 5-HT receptors.  To date, there have been no studies of a potential rat strain 
difference in the response to either 5-HT2 or 5-HT3 receptor active compounds.  
Therefore, in the following experiment, a potential strain difference in the sexual 
behavioral response to the 5-HT2A/2C receptor antagonist, ketanserin, was examined.  
Emphasis was placed on the 5-HT2A/2C receptor because this receptor has been most 
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thoroughly investigated for it’s impact on the response to 5-HT1A receptor agonists 
(Uphouse and Guptarak, 2010) and because such antagonists can augment the effects of 
SSRIs  (Boothman et al., 2006; Cremers et al., 2004; Marek et al., 2003; Marek et al., 
2005).  Such augmentation is thought to result from the ability of 5-HT2A/2C receptor 
antagonists to increase firing of 5-HT neurons in the dorsal raphe nucleus (DRN) 
(Boothman et al., 2003; Boothman and Sharp, 2005; Cremers et al., 2004).  Therefore, 5-
HT2A/2C receptor antagonists, by increasing extracellular 5-HT in lordosis-controlling 
brain areas, would be expected to reduce lordosis behavior both by increasing activation 
of inhibitory 5-HT1A receptors and by antagonizing any protective effect of 5-HT2A/2C 
receptors.   Because of the greater sensitivity of Sprague-Dawley rats to the lordosis-
inhibiting effect of a 5-HT1A receptor agonist but lesser sensitivity to the SSRI, 
fluoxetine, it was hypothesized that Sprague-Dawley females might show a greater 
sensitivity to antagonism of 5-HT2A/2C receptors.   
2.  Methods 
2.1 Materials 
 Estradiol benzoate (EB), progesterone (P), sesame seed oil, the selective serotonin 
reuptake inhibitor (SSRI), fluoxetine (methyl [3-phenyl-3-4-(trifluoromethyl)-phenoxy] 
propyl] ammonium chloride), and the 5-HT2A/2C  receptor antagonist, ketanserin (3-[2-[4-
(4-fluorbenzoyl)-1-piperdinyl]ethyl]- 2,4(1H,3H)-quinazolinedione), were purchased 
from Sigma-Aldrich Chemical Company (St. Louis, MO).  Isoflurane (AErrane®) and 
suture materials were purchased from Butler Schein Animal Health (Dublin, OH).  Food 
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(Rodent Lab Diet 5001) was purchased from Lab Animal Supply (Highland Village, TX, 
USA).  All other supplies were purchased from Fisher Scientific (Houston, TX, USA). 
2.2 Animals, housing and surgical procedures 
Female Fischer and Sprague-Dawley rats were purchased from Charles River 
Laboratories (Wilmington, MA) and housed 2 per cage in standard shoebox caging 
(45.72 × 24.13 × 20.59 cm).  The housing area was maintained at 25° C and 65% 
humidity with lights on from 12:00 midnight to 12:00 noon.  Animals varied in their age 
within experiments but were always matched between Fischer and Sprague-Dawley 
females and counterbalanced between treatment conditions.  Food and water were 
available ad libitum. Rats were ovariectomized under AErrane® anesthesia as described 
previously (White and Uphouse, 2004) approximately 2 weeks after their arrival.  
Hormonal priming was with EB followed 48 hours later with P and occurred 10 to 14 
days after ovariectomy.  Hormones were dissolved in sesame seed oil and injected 
subcutaneously.  Since Fischer and Sprague-Dawley females differ in their body weight, 
hormones were administered per body weight (0.067 µg/g EB and 3.333 µg/g P).  At the 
time of behavioral testing, in the first experiment, females were 12 to 22 weeks old; the 
mean ± standard error (S.E.) body weights of Fischer and Sprague-Dawley were 162.7 ± 
1.55 and 273.0 ± 4.15, respectively; in the second experiment, females were 13 to 17 
weeks old with mean ± S.E. body weights of Fischer and Sprague-Dawley rats of 166.6 ± 
2.05 and 264.2 ± 3.85, respectively.  All procedures were in accordance with the NIH 
Guide for the Care and Use of Animals in Research and were approved by the 
Institutional Animal Care and Use Committee at Texas Woman's University. 
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2.3 Treatment of animals 
On the day of testing, 4 to 6 hr after P injection, rats were pretested for sexual 
behavior as previously described (White and Uphouse, 2004).  Rats were placed into the 
home cage of a sexually active male and behavior was monitored until 10 mounts had 
occurred or for a maximum of 10 min.  In the first experiment, immediately following the 
pretest, females were injected intraperitoneally (ip) with deionized water (DI) or with 
0.416, 0.5, 0.75, 1.0, 2.0, 5.0 or 10.0 mg/kg of the 5-HT2A/2C receptor antagonist, 
ketanserin, in a volume of 1 ml/kg.  Behavioral testing began immediately after the 
ketanserin injection and was recorded for 30 consecutive min.  Data were grouped into 
the first and second 15 min intervals for statistical analysis.  In the second experiment, 
immediately following the pretest, females were injected with fluoxetine (10 mg/kg; 
volume of 1 ml/kg) or deionized water (DI).  Fifteen min later, DI treated rats were 
injected intraperitoneally with 1 mg/kg ketanserin; fluoxetine-treated rats were injected 
with ketanserin (1 mg/kg) or DI.  This led to three groups: fluoxetine only, ketanserin 
only, and the combination of fluoxetine and ketanserin.  Fifteen min after the ketanserin 
or DI treatment, females were placed into the male’s cage for 15 min of sexual behavioral 
testing.  Data for the 15 min interval were grouped for statistical comparison. 
2.4 Behavioral testing procedures 
The lordosis/mount (L/M) ratio (number of lordosis reflexes by the female 
divided by the number of mounts by the male) and lordosis quality scores (on a scale of 1 
to 4) were measured as previously described (White and Uphouse, 2004).  Lordosis 
quality was calculated as the sum of the individual lordosis quality scores divided by the 
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number of lordosis responses.  Proceptivity was measured by the presence or absence of 
hopping and darting behavior.  L/M ratios, lordosis quality scores, and mounts were 
recorded for the pretest and for the 15-min test intervals.  Proceptive behavior was 
recorded as present or absent for the pretest and the entire test interval. 
2.5 Statistical procedures 
 For the first experiment, L/M ratios, lordosis quality and number of mounts were 
analyzed by repeated measures analysis of variance (ANOVA) with strain and dose of 
ketanserin as independent factors and with first or second testing interval as the repeated 
factor.  L/M ratios were subjected to regression on dose for estimation of the IC50.  IC50 
(dose leading to 50% of maximum effect) was defined as an L/M ratio of 0.5.  For 
experiment 2, strain and treatment condition were independent factors and time relative 
to pretest was the repeated factor.  Proceptivity data were analyzed using Chi-Square and 
Fischer’s Exact Test procedures.  Data were analyzed with SPSS version 19.0 (for PC) 
and the statistical reference was Zar (2010).  Post-hoc Tukey comparisons were computed 
manually and an alpha of 0.05 was required for statistical significance. 
3. Results 
 The effects of ketanserin on lordosis behavior of Fischer and Sprague-Dawley 
females are shown in Figure 3.1.  There was a significant effect of strain (F1,109 = 5.14, 
 p ≤ 0.025) and dose of ketanserin (F7, 109 = 11.47, p ≤ 0.001).  The strain difference 
reflected a lower L/M ratio of Sprague-Dawley than Fischer females that was most 
evident during the second 15 min interval after ketanserin treatment.  In comparison to 
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the DI water control, Sprague-Dawley females showed a significant decline in the L/M 
ratio at lower doses of ketanserin than were evident in Fischer females.  However, the 
IC50 for the two strains were relatively similar.  For the first 15 min interval, the IC50 for 
Fischer and Sprague-Dawley, respectively, was 12.73 and 10.62 mg/kg.  For the second 
15 min interval, the IC50 for Fischer and Sprague-Dawley, respectively, were 6.12 and 7.5 
mg/kg.  There was a significant difference between the first and second 15 min interval 
(ANOVA for time after ketanserin, F1,109 = 39.93, p ≤ 0.001), but there was no interaction 
between time and strain (p > 0.05) and none of the interactions with strain were 
significant (all p > 0.05).   
 The effects of ketanserin on lordosis quality were similar to those for L/M ratios 
and were also more obvious during the second 15 min interval (ANOVA for time, F1,106 = 
9.27, p ≤ 0.003, see Figure 3.2).  There was a significant effect of the dose of ketanserin 
on lordosis quality (F7,106= 4.14 , p ≤ 0.001) and, as for L/M ratios, quality scores were 
slightly more likely to be affected in Sprague-Dawley than in Fischer females (ANOVA 
for strain, F1,106 = 9.21, p ≤ 0.003).  Nevertheless, none of the interactions with strain or 
dose were significant (all p > 0.05). 
 Fischer and Sprague-Dawley females received comparable mounting from the 
males. The only significant effect was between strain and time (F1,110 = 5.72, p ≤ 0.018) 
that reflected a decline between the first and second 15 min intervals in number of 
mounts for Fischer, but not Sprague-Dawley rats.  For Fischer rats, the means ± S.E. 
numbers of mounts for the 15 and 30 min intervals, respectively, were 20.5 ± 0.97 and 
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17.8 ± 0.98; for Sprague-Dawley females, the means ± S.E. were 19.2 ± 0.98 and 19.8 ± 
0.99, respectively. 
 Prior to injection, a greater proportion of Sprague-Dawley than Fischer females 
showed evidence of proceptivity (for Fischer and Sprague-Dawley, respectively, 61.9% 
and 80.9%; Fisher Exact test, p ≤ 0.029).  After injection, there was a significant effect of 
the treatment in Fischer rats (Chi-Square = 20.35, df = 7, p ≤ 0.005) but this reflected a 
decrease in proceptivity relative to the DI control.  When only ketanserin groups were 
compared, there was no dose effect (p > 0.05).  There was no effect of treatment on 
proceptivity of Sprague-Dawley females (Chi-Square = 9.3, df = 7, p > 0.05) (Figure 
3.3).  However, when groups were collapsed across the dose of ketanserin and compared 
to the DI control, proceptivity of ketanserin-treated females was significantly reduced in 
both strains (see Figure 3 inset; for Fischer and Sprague-Dawley, respectively, Chi-
Square = 13.08, p ≤ 0.001 and Chi-Square = 4.93, p ≤ 0.026). 
 The second experiment was designed to determine if fluoxetine and ketanserin 
would amplify the effects of either drug alone.   A dose of 10 mg/kg fluoxetine (Miryala 
et al., 2013) and 1 mg/kg ketanserin (Experiment 1) were chosen and the effects of either 
drug or their combination were compared.  For L/M ratios, there was a significant effect 
of the type of treatment (F2, 45 = 4.43, p ≤ 0.017), time (F1, 45 = 90.71, p ≤ 0.0001) and 
their interaction (F2, 45 = 3.39, p ≤ 0.042) (Figure 3.4).  Neither strain nor any interactions 
with strain were significant.  All treatment conditions reduced L/M ratios relative to their 
pretest (q45, 2 = 2.85, p < 0.05) but L/M ratios after fluoxetine injection were higher than 
in the other 2 groups.  This was especially evident in Fischer females where fluoxetine-
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treated rats had significantly higher L/M ratios than the other two treatment conditions 
(for ketanserin, alone, and both drugs, respectively, q3, 45 = 3.65 and 5.25, p ≤ 0.05).  For 
Sprague-Dawley females, L/M ratios of fluoxetine-treated rats did not differ significantly 
from either of the 2 other groups (Tukey’s q3, 45, all p > 0.05).  In neither strain did the 
L/M ratios of rats treated with both ketanserin and fluoxetine differ from L/M ratios after 
ketanserin, alone (all p > 0.05). 
Two females (one from each strain) failed to show any lordosis behavior after 
treatment and were excluded from the analysis for lordosis quality.  For the remaining 
rats, there was not a differential effect of treatment on lordosis quality (p > 0.05; see 
Table 3.1).  Although there was a slight effect of strain (F1, 43 = 5.50, p ≤ 0.05) and time 
(F1, 43 =18.42, p ≤ 0.001), lordosis quality remained relatively high throughout the testing 
period with the exception of Sprague-Dawley female given both drugs.  For this 
treatment, in this strain, lordosis quality was significantly reduced relative to the pretest 
(q3, 43 = 5.93, p ≤ 0.05) and the combination of the two drugs differed from both 
fluoxetine only and ketanserin only groups (respectively, q3, 43 = 5.07 and 5.33, p ≤ 0.05).    
As in the first experiment, more Sprague-Dawley than Fischer females showed 
proceptivity (34.6% of Fischer and 92% of Sprague-Dawley females were proceptive; 
Chi-Square =17.95, df = 1, p ≤ 0.001).  Rats assigned to different treatment conditions 
did not differ in the pretest (Chi-Square for Fischer = 0.552 and Sprague-Dawley = 1.0,  
p > 0.05) but there was a treatment-dependent effect on proceptivity after 
treatment (respectively for Fischer and Sprague-Dawley females, Chi-Square = 7.63 and 
7.29, df = 2, p ≤ 0.03) (Figure 3.5).  For Sprague-Dawley females, the treatment effect 
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resulted from higher proceptivity in fluoxetine-treated rats compared to the other 2 
groups (for ketanserin plus fluoxetine and ketanserin, alone, respectively, Chi-Square = 
6.34 and 4.96, df = 1, p ≤ 0.04).  Although a similar pattern was present in Fischer 
females, because of the low overall proceptivity in Fischer rats, there were no treatment 
effects.  Strain differences were present only in rats given fluoxetine (Chi-Square = 5.52, 
df = 1, p ≤ 0.04) and reflected the lower overall proceptivity of Fischer females rather 
than a strain difference in response to the treatment. 
There were no differences between strains or among treatments on the number of 
mounts received by the females.  The mean ± S.E. number of mounts for Fischer rats for 
fluoxetine only, ketanserin only, and their combination, respectively, were 21.7 ± 2.6, 
15.42 ± 2.31 and 14.7 ± 1.84;  the average number of mounts for fluoxetine only, 
ketanserin only and their combination for Sprague-Dawley, respectively, were 14.4 ± 
2.48, 16.7 ±  2.0, and 13.1 ± 1.76.   
4. Discussion 
 The present study was designed to expand information about the strain differences 
in the 5-HT system which could potentially account for the lower sensitivity of Sprague-
Dawley females to the lordosis inhibiting effects of fluoxetine but greater sensitivity to 
the lordosis-inhibiting 5-HT1A receptor agonist, (+/-) 8-hydroxy-2- (di-n-propylamino) 
tetralin (8-OH-DPAT).  Ketanserin reduced lordosis behavior in both strains and 
inhibition was greatest during the second 15 min test interval (15 to 30 min after 
injection), consistent with earlier studies showing time-dependent effects of ketanserin 
following infusion into the ventromedial nucleus of the hypothalamus (Sinclair-Worley 
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and Uphouse, 2004; Wolf et al., 1998).  In comparison to robust strain differences in the 
lordosis-inhibitory effect of the 5-HT1A receptor agonist, 8-OH-DPAT (Uphouse et al., 
2002), strain differences in the response to the 5-HT2A/2C receptor antagonist were 
relatively modest and evident only during the 2nd 15 min test interval.  Nevertheless, the 
IC50 was comparable in the two strains.  However, that Sprague-Dawley females showed 
a slightly greater effect of ketanserin may indicate a greater dependency of this strain on 
the lordosis-facilitating effects of 5-HT2A/2C receptors. 
 Ketanserin’s ability to reduce lordosis behavior is believed to result from its 
antagonism of 5-HT2A/2C receptors (Mendelson, 1992; Uphouse and Guptarak, 2010) but 
whether 5-HT2A or 5-HT2C receptors are responsible is unclear.  Ketanserin blocks both  
5-HT2A and 5-HT2C receptors but is reported to have the greater affinity for 5-HT2A 
receptors (Hoyer et al., 2002).  However, in the ventromedial hypothalamus (VMN), it is 
5-HT2C receptors that have been implicated in lordosis modulation (Wolf et al., 1999).  In 
this brain area, the 5-HT2B/2C receptor antagonist, SB206553, but not the 5-HT2A receptor 
antagonist, MDL 100,907, mimicked effects of ketanserin.  In contrast, 5-HT2A receptors 
may be responsible for 5-HT2 receptor-mediated drug effects in the medial preoptic area 
(Gonzalez et al., 1997).  Therefore, both 5-HT2A and 5-HT2C receptors and several brain 
areas may contribute to the decline in lordosis behavior after the systemic treatment with 
ketanserin.   
 Differences between Fischer and Sprague-Dawley rats have been repeatedly noted 
with considerable evidence for differential functioning of the 5-HT system (Burnet et al., 
1994; Fernandez et al., 2003; Miryala et al., 2013; Rosecrans et al., 1986; Uphouse et al., 
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2002).  Of special relevance to the current study is evidence that Fischer rats may have 
more SERT in the DRN than other rat strains (Burnet et al., 1996; Fernandez et al., 
2003).  If so, relative to Sprague-Dawley females, Fischer rats would be expected to have 
less extracellular 5-HT in the DRN following treatment with the SERT blocker, 
fluoxetine.  With less consequent activation of the somatodendritic auto inhibitory 5-
HT1A receptors, Fischer females might show a greater elevation of extracellular 5-HT in 
lordosis-relevant brain areas such as the VMN following treatment with SSRIs.  With 
fluoxetine’s additional antagonism at 5-HT2 receptors (Jenck et al., 1993; Palvimaki et 
al., 1996), the increase in 5-HT release would disrupt the balance between the lordosis-
inhibiting (5-HT1A) and lordosis-facilitating (5-HT2C) receptors to a greater extent in 
Fischer than in Sprague-Dawley females.    
 In contrast, following treatment with a 5-HT1A receptor agonist, the higher 
midbrain SERT of Fischer females would not impact the strain response since the agonist 
would directly activate lordosis-inhibiting 5-HT1A receptors to reveal a greater sensitivity 
of Sprague-Dawley females to the 5-HT1A receptor agonist.  
 The current studies offer indirect evidence that strain differences between Fischer 
and Sprague-Dawley females do not include 5-HT2 receptors.  5-HT2 receptors in the 
midbrain decrease firing of DRN neurons possibly by activation of inhibitory GABA 
neurons (Boothman et al., 2003; Boothman and Sharp, 2005) and 5-HT2 receptor 
antagonists increase release of 5-HT in areas terminal to DRN neurons (Boothman et al., 
2006).  In the current study, blocking 5-HT2 receptors with ketanserin would be expected 
to increase DRN firing and release of 5-HT and thereby increase activation of 5-HT1A 
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receptors and reduce activation of 5-HT2 receptors in lordosis-relevant brain areas.  It 
was, therefore, expected that Sprague-Dawley rats would show greater sensitivity to 
ketanserin, but this was not the case.  In the absence of a remarkable strain difference in 
the response to 5-HT2 receptor antagonism, the resulting disruption of balance between 
the inhibitory and facilitatory 5-HT2 receptors would be substantial in both strains but 
would produce a minimal strain difference, as observed in the current study.  
 Since fluoxetine not only blocks SERT but also blocks 5-HT2 receptors (Jenck et 
al., 1993; Palvimaki et al., 1996), it was anticipated that ketanserin plus fluoxetine would 
be additive in their effect on lordosis behavior.  Such an accentuated response in 
hippocampal extracellular 5-HT has been reported in Fischer females following treatment 
with another SSRI, citalopram, but not following fluoxetine (Fernandez et al., 2003).  
However, such an augmentation following fluoxetine has been reported by other 
investigators (Cremers et al., 2004).   Nevertheless, in the current study, fluoxetine and 
ketanserin were not additive in their effect on lordosis behavior and there was no 
evidence of a strain difference. 
 Therefore, the current studies provide evidence that previously reported difference 
between Fischer and Sprague-Dawley females in response to fluoxetine or a 5-HT1A 
receptor agonist are unlikely to depend on a strain difference in 5-HT2 receptor action.  
However, since ketanserin blocks both 5-HT2A and 5-HT2C receptors, more selective 5-
HT2 receptor antagonists are needed to definitively eliminate 5-HT2 receptors from 
consideration.  Moreover, only a single dose of fluoxetine and ketanserin were examined 
in the current study.  Additional dose combinations would be useful to completely rule 
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out such a strain difference in 5-HT2 receptors and/or additive/synergistic effects of 5-
HT2 receptor antagonists and fluoxetine.  Finally, it is important to note that ketanserin 
also blocks alpha-1 adrenergic receptors (Hoyer et al., 1987; Marwood, 1994) so that we 
cannot rule out possible strain differences in these receptors that could have masked the 
existence of a strain difference for 5-HT2 receptor antagonism. 
5. Conclusions 
 In summary, ketanserin dose-dependently inhibited lordosis behavior in both 
Fischer and Sprague-Dawley females.  Strain differences, though present, were modest 
and are more likely to reflect the greater sensitivity of Sprague-Dawley females to 5-
HT1A receptor activation than a strain difference in 5-HT2 receptor functioning.  In 
addition, ketanserin and fluoxetine were not additive in their effect on lordosis, and the 
combined treatment reflected primarily the lordosis inhibition with ketanserin alone.   
Acknowledgments 
 Research supported by NIH HD28419 and by a TWU institutional research 
support grant.  Special appreciation is given to Ms. Aminata Diaby for technical 
assistance. We thank Ms. Karolina Blaha-Black and Mr. Dan Wall for animal care. 
 
References 
Boothman LJ, Allers KA, Rasmussen K, Sharp T. Evidence that central 5-HT2A and 5-
HT2B/C receptors regulate 5-HT cell firing in the dorsal raphe nucleus of the 
anaesthetized rat. Br J Pharmacol 2003;139:998-1004. 
62 
 
Boothman LJ, Mitchell SN, Sharp T. Investigation of the SSRI augmentation properties 
of 5-HT(2) receptor antagonists using in vivo micro dialysis. Neuropharmacology 
2006;50:726-732. 
Boothman LJ, Sharp T. A role for midbrain raphe gamma amino butyric acid neurons in 
5-hydroxytryptamine feedback control. Neuroreport 2005;16:891-896. 
Burnet PW, Mefford IN, Smith CC, Gold PW, Sternberg EM. Hippocampal 5-HT1A 
receptor binding site densities, 5-HT1A receptor messenger ribonucleic acid 
abundance and serotonin levels parallel the activity of the hypothalamus-pituitary-
adrenal axis in rats. Behav Brain Res 1996;73:365-368. 
Burnet PW, Michelson D, Smith MA, Gold PW, Sternberg EM. The effect of chronic 
imipramine administration on the densities of 5-HT1A and 5-HT2 receptors and 
the abundances of 5-HT receptor and transporter mRNA in the cortex, 
hippocampus and dorsal raphe of three strains of rat. Brain Res 1994;638:311-
324. 
Clayton A, Keller A, McGarvey EL. Burden of phase-specific sexual dysfunction with 
SSRIs. J Affect Disord 2006;91:27-32. 
Clayton AH. Female sexual dysfunction related to depression and antidepressant 
medications. Curr Womens Health Rep 2002;2:182-187. 
Cremers TI, Giorgetti M, Bosker FJ, Hogg S, Arnt J, Mork A, Honig G, Bogeso KP, 
Westerink BH, den Boer H, Wikstrom HV, Tecott LH. Inactivation of 5-HT(2C) 
receptors potentiates consequences of serotonin reuptake blockade. 
Neuropsychopharmacology 2004;29:1782-1789. 
63 
 
Dhabhar FS, McEwen BS, Spencer RL. Stress response, adrenal steroid receptor levels 
and corticosteroid-binding globulin levels--a comparison between Sprague-
Dawley, Fischer 344 and Lewis rats. Brain Res 1993;616:89-98. 
Fernandez F, Sarre S, Launay JM, Aguerre S, Guyonnet-Duperat V, Moisan MP, Ebinger 
G, Michotte Y, Mormede P, Chaouloff F. Rat strain differences in peripheral and 
central serotonin transporter protein expression and function. Eur J Neurosci 
2003;17:494-506. 
Fuller RW, Wong DT, Robertson DW. Fluoxetine, a selective inhibitor of serotonin 
uptake. Med Res Rev 1991;11:17-34. 
Gelenberg AJ, Delgado P, Nurnberg HG. Sexual side effects of antidepressant drugs. 
Curr Psychiatry Rep 2000;2:223-227. 
Gobert A, Rivet JM, Cistarelli L, Millan MJ. Potentiation of the fluoxetine-induced 
increase in dialysate levels of serotonin (5-HT) in the frontal cortex of freely 
moving rats by combined blockade of 5-HT1A and 5-HT1B receptors with WAY 
100,635 and GR 127,935. J Neurochem 1997;68:1159-1163. 
Gonzalez MI, Greengrass P, Russell M, Wilson CA. Comparison of serotonin receptor 
numbers and activity in specific hypothalamic areas of sexually active and 
inactive female rats. Neuroendocrinology 1997;66:384-392. 
Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. 
Antidepressant-induced sexual dysfunction. Ann Pharmacother 2002;36:1577-
1589. 
64 
 
Guptarak J, Sarkar J, Hiegel C, Uphouse L. Role of 5-HT(1A) receptors in fluoxetine-
induced lordosis inhibition. Horm Behav 2010;58:290-296. 
Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 
5-HT receptors. Pharmacol Biochem Behav 2002;71:533-554. 
Hoyer D, Vos P, Closse A, Pazos A, Palacios JM, Davies H. [3H]ketanserin labels 5-HT2 
receptors and alpha 1-adrenoceptors in human and pig brain membranes. Naunyn 
Schmiedebergs Arch Pharmacol 1987;335:226-230. 
Hunter AJ, Hole DR, Wilson CA. Studies into the dual effects of serotonergic 
pharmacological agents on female sexual behavior in the rat: preliminary 
evidence that endogenous 5HT is stimulatory. Pharmacol Biochem Behav 
1985;22:5-13. 
Jenck F, Moreau JL, Mutel V, Martin JR, Haefely WE. Evidence for a role of 5-HT1C 
receptors in the antiserotonergic properties of some antidepressant drugs. Eur J 
Pharmacol 1993;231:223-229. 
Kosten TA, Ambrosio E. HPA axis function and drug addictive behaviors: insights from 
studies with Lewis and Fischer 344 inbred rats. Psychoneuroendocrinol 
2002;27:35-69. 
Marek GJ, Carpenter LL, McDougle CJ, Price LH. Synergistic action of 5-HT2A 
antagonists and selective serotonin reuptake inhibitors in neuropsychiatric 
disorders. Neuropsychopharmacology 2003;28:402-412. 
65 
 
Marek GJ, Martin-Ruiz R, Abo A, Artigas F. The selective 5-HT2A receptor antagonist 
M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. 
Neuropsychopharmacology 2005;30:2205-2215. 
Marwood JF. Influence of alpha 1-adrenoceptor antagonism of ketanserin on the nature 
of its 5-HT2 receptor antagonism. Clin Exp Pharmacol Physiol 1994;21:955-961. 
Maswood N, Caldarola-Pastuszka M, Uphouse L. 5-HT3 receptors in the ventromedial 
nucleus of the hypothalamus and female sexual behavior. Brain Res 1997;769:13-
20. 
Maswood N, Caldarola-Pastuszka M, Uphouse L. Functional integration among 5-
hydroxytryptamine receptor families in the control of female rat sexual behavior. 
Brain Res 1998;802:98-103. 
Maswood N, Sarkar J, Uphouse L. Modest effects of repeated fluoxetine on estrous 
cyclicity and sexual behavior in Sprague Dawley female rats. Brain Res 
2008;1245:52-60. 
Mendelson SD. A review and reevaluation of the role of serotonin in the modulation of 
lordosis behavior in the female rat. Neurosci Biobehav Rev 1992;16:309-350. 
Mendelson SD, Gorzalka BB. A facilitatory role for serotonin in the sexual behavior of 
the female rat. Pharmacol Biochem Behav 1985;22:1025-1033. 
Mendelson SD, Gorzalka BB. Sex differences in the effects of 1-(m-
trifluoromethylphenyl) piperazine and 1-(m-chlorophenyl) piperazine on 
copulatory behavior in the rat. Neuropharmacology 1990;29:783-786. 
66 
 
Miryala CS, Hiegel C, Uphouse L. Sprague-Dawley and Fischer females differ in acute 
effects of fluoxetine on sexual behavior. Journal of Sexual Medicine 
2013;10:350-361. 
Palvimaki EP, Roth BL, Majasuo H, Laakso A, Kuoppamaki M, Syvalahti E, Hietala J. 
Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c 
receptor. Psychopharmacology (Berl) 1996;126:234-240. 
Perry KW, Fuller RW. Effect of fluoxetine on serotonin and dopamine concentration in 
micro dialysis fluid from rat striatum. Life Sci 1992;50:1683-1690. 
Perry KW, Fuller RW. Extracellular 5-hydroxytryptamine concentration in rat 
hypothalamus after administration of fluoxetine plus L-5-hydroxytryptophan. J 
Pharm Pharmacol 1993;45:759-761. 
Rosecrans JA, Robinson SE, Johnson JH, Mokler DJ, Hong JS. Neuroendocrine, biogenic 
amine and behavioral responsiveness to a repeated foot-shock-induced analgesia 
(FSIA) stressor in Sprague-Dawley (CD) and Fischer-344 (CDF) rats. Brain Res 
1986;382:71-80. 
Sghendo L, Mifsud J. Understanding the molecular pharmacology of the serotonergic 
system: using fluoxetine as a model. J Pharm Pharmacol 2011;64:317-325. 
Sinclair-Worley L, Uphouse L. Effect of estrogen on the lordosis-inhibiting action of 
ketanserin and SB 206553. Behav Brain Res 2004;152:129-135. 
Tao R, Fray A, Aspley S, Brammer R, Heal D, Auerbach S. Effects on serotonin in rat 
hypothalamus of D-fenfluramine, aminorex, phentermine and fluoxetine. Eur J 
Pharmacol 2002;445:69-81. 
67 
 
Tavoulari S, Forrest LR, Rudnick G. Fluoxetine (Prozac) binding to serotonin transporter 
is modulated by chloride and conformational changes. J Neurosci 2009;29:9635-9643. 
Uphouse L. Female gonadal hormones, serotonin, and sexual receptivity. Brain Res Brain 
Res Rev 2000;33:242-257. 
Uphouse L, Andrade M, Caldarola-Pastuszka M, Jackson A. 5-HT1A receptor 
antagonists and lordosis behavior. Neuropharmacology 1996;35:489-495. 
Uphouse L, Andrade M, Caldarola-Pastuszka M, Maswood S. Hypothalamic infusion of 
the 5-HT2/1C agonist, DOI, prevents the inhibitory actions of the 5-HT1A 
agonist, 8-OH-DPAT, on lordosis behavior. Pharmacol Biochem Behav 
1994;47:467-470. 
Uphouse L, Caldarola-Pastuszka M. Female sexual behavior following intracerebral 
infusion of the 5-HT1A agonist, 8-OH-DPAT, into the medial preoptic area. Brain 
Res 1993;601:203-208. 
Uphouse L, Guptarak J. Serotonin and Sexual Behavior.  In: Muller, CP and Jacobs, BL, 
editor. Handbook of the Neurobiology of Serotonin. New York: Academic Press, 
2010, p 346-366. 
Uphouse L, Hensler JG, Sarkar J, Grossie B. Fluoxetine disrupts food intake and estrous 
cyclicity in Fischer female rats. Brain Res 2006;1072:79-90. 
Uphouse L, Maswood S, Jackson A, Brown K, Prullage J, Myers T, Shaheen F. Strain 
differences in the response to the 5-HT1A receptor agonist, 8-OH-DPAT. 
Pharmacol Biochem Behav 2002;72:533-542. 
68 
 
White S, Uphouse L. Estrogen and progesterone dose-dependently reduce disruptive 
effects of restraint on lordosis behavior. Horm Behav 2004;45:201-208. 
Wolf A, Caldarola-Pastuszka M, DeLashaw M, Uphouse L. 5-HT2C receptor 
involvement in female rat lordosis behavior. Brain Res 1999;825:146-151. 
Wolf A, Caldarola-Pastuszka M, Uphouse L. Facilitation of female rat lordosis behavior 
by hypothalamic infusion of 5-HT(2A/2C) receptor agonists. Brain Res 
1998;779:84-95. 
Zar J. Biostatistical Analysis. Upper Saddle River, New Jersey: Pearson Prentice Hall, 
2010. 
 
 
 
 
69 
 
 
Fig.  3.1. L/M ratio after varying doses of ketanserin treatment. 
Hormonally primed, ovariectomized rats were pretested for sexual behavior 4 to 6 hr after 
progesterone.  Rats were then injected with deionized (DI) water or with 0.416, 0.5, 0.75, 
1, 2, 5 or 10 mg/kg of ketanserin.  Fifteen minutes later, rats were again tested for two 
consecutive 15 min intervals.  Data are the mean ± SE L/M ratios for the two 15 min 
interval after injection with deionized water or ketanserin.  Pretest L/M ratios (0.99 ± 
0.003 and 0.98 ± 0.007, respectively, for Fischer and Sprague-Dawley females) did not 
differ.  The Ns for Fischer rats for (DI) water or 0.416, 0.5, 0.75, 1, 2, 5 or 10 mg/kg of 
ketanserin, respectively, were 5, 8, 9, 6, 10, 5, 13 and 7.  Ns for Sprague-Dawley rats, 
respectively, were 5, 8, 10, 6, 9, 5, 14 and 6.  *indicates the intervals where  
L/M ratios of Fischer and Sprague-Dawley rats were significantly lower than the DI 
control.    
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Fig. 3.2. Lordosis quality after ketanserin treatment. 
Data are the mean ± SE lordosis quality score for the pretest and two 15 intervals after 
treatment with ketanserin or deionized water (DI) and are for the same rats as in Figure 
3.1. The Ns for Fischer rats for DI water or 0.416, 0.5, 0.75, 1, 2, 5 or 10 mg/kg of 
ketanserin, respectively, were 5, 8, 9, 6, 10, 5, 13 and 7.  Ns for Sprague-Dawley rats, 
respectively, were 5, 8, 10, 6, 9, 5, 14 and 6.  *indicates the intervals where lordosis 
quality of Fischer and Sprague-Dawley rats were significantly lower than the DI control.    
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Fig. 3.3. Effects of ketanserin on proceptivity. 
Data are the percentage of rats showing proceptivity after the various doses of ketanserin 
treatment and for the same rats as in Figure 3.1.  The inset shows the percentage of rats 
when collapsed across doses of ketanserin.  *indicates significant decline in proceptivity 
relative to the DI control, within strain. 
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Fig. 3.4. Ketanserin and fluoxetine are not additive for lordosis inhibition. 
Hormonally primed, ovariectomized rats were pretested for sexual behavior 4 to 6 hr after 
progesterone.  Rats were then injected with 10 mg/kg fluoxetine or deionized water (DI).   
Fifteen minutes later DI injected rats were injected with 1 mg/kg ketanserin; fluoxetine-
treated rats were injected with 1 mg/kg ketanserin or DI.  This led to three groups, 
fluoxetine only, ketanserin only, fluoxetine and ketanserin.  Fifteen minutes later, rats 
were again tested for 15 consecutive min.  Data are the mean ± SE L/M ratios for the 
pretest and 15 consecutive min after injection.  The Ns for Fischer rats given fluoxetine, 
ketanserin, or both drugs were 8, 7 and 11.  Ns for Sprague-Dawley rats given fluoxetine, 
ketanserin, or both drugs were 7, 7 and 11.  *indicates significant difference from the 
pretest within treatment, # indicates a difference from fluoxetine within strain.  
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Fig. 3.5. Effects of fluoxetine (FLX), ketanserin (KET), and their combination (BOTH) 
on proceptivity. 
Data are the percentage of rats showing proceptivity after the 3 treatments and are for the 
same rats as in Figure 3.4.  Data are for the Pretest and the 15 min interval after 
treatment.  *indicates a significant difference from both the pretest and fluoxetine, within 
strain. 
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Table 3.1 
Treatment effects on lordosis quality scores 
 Treatment 
Strain Pretest Fluoxetine  
10 mg/kg 
Ketanserin  
1 mg/kg  
Fluoxetine +     
Ketanserin 
Fischer 2.8 ± 0.04 2.9 ± 0.04 2.8 ± 0.07 2.8 ± 0.07 
Sprague-Dawley 2.8 ± 0.05 2.7 ± 0.12 2.7 ± 0.13 2.3 ± 0.19*# 
*Indicates significantly different from Fischer within treatment  
#Indicates significantly different from all other groups within strain 
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                                             CHAPTER IV 
         DISCUSSION  
 With the discovery of fluoxetine and its efficacy for treatment of depression, the 
antidepressant has been widely used not only for depression but for other mood disorders 
of greater prevalence in females (Hashimoto, 2010; Nazari et al., 2013).  However, in 
spite of its efficacy for these mood disorders, fluoxetine causes sexual dysfunction in a 
large proportion of patients and the onset of sexual dysfunction precedes the clinical 
manifestations of drug efficacy for depression.  As a consequence, sexual dysfunction is a 
major factor in patient noncompliance (Michelson et al., 2000).  However, not all patients 
exhibit such sexual dysfunction.  The main objective of this study was to provide 
information as to why some females experience severe sexual dysfunction following 
treatment with fluoxetine while others show minimal, if any, effects.  Specifically, the 
current studies were designed to determine if Fischer and Sprague-Dawley female rats 
differed in their sexual behavioral response after an acute treatment with fluoxetine.   The 
major outcomes of this study were: (i) consistent with prior studies, fluoxetine reduced 
female rat sexual behavior in both hormonally-primed, ovariectomized and in naturally-
cycling rats; (ii) hormonally primed, ovariectomized rats were more sensitive to the 
lordosis-inhibiting effects of fluoxetine than the intact, naturally cycling females; (iii) in 
both hormonally-primed and naturally cycling rats, Sprague-Dawley females were less 
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sensitive to the lordosis-inhibiting effects of fluoxetine than Fischer females; (iv) a 5-
HT2A/2C receptor antagonist, ketanserin, reduced lordosis behavior in both strains with a 
slightly greater effect in Sprague-Dawley females; but the difference was modest in 
comparison to the strain difference in response to fluoxetine; and (v) the combination of 
fluoxetine and ketanserin did not amplify negative effects on lordosis behavior relative to 
the individual drugs alone.   
 Since recognition of the sexual side effects of fluoxetine, there has been 
considerable discussion about the responsible mechanisms with most emphasis placed on 
the 5-HT system (Haenisch and Bönisch, 2011).  Fluoxetine increases extracellular 5-HT 
by blocking the SERT and thereby has the potential to increase activation of all 5-HT 
receptors (Malagié et al., 1995; Tao et al., 2002).  Regarding the sexual side effects in 
female rats, activation of 5-HT1A receptors is thought to contribute to the sexual 
dysfunction following fluoxetine treatment (Guptarak et al., 2010).  Because of the 
greater sensitivity of Sprague-Dawley females to 5-HT1A receptor activation, it was 
hypothesized that Sprague-Dawley females might be more sensitive to fluoxetine, but this 
was not the case.  Fischer females were more sensitive to the lordosis-inhibiting effect of 
fluoxetine than Sprague-Dawley females and this was evident in both hormonally-primed 
and naturally cycling rats.  The greater sensitivity of Fischer females to the acute effect of 
fluoxetine is consistent with prior studies demonstrating a greater effect of repeated 
fluoxetine on estrous cyclicity in this strain (Maswood et al., 2008; Uphouse et al., 2006).  
 Since, in the current experiment with ovariectomized females, hormonal treatment 
was administered according to body weight, the heavier Sprague-Dawley females 
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received a greater absolute amount of hormones.  This could have been a confounding 
factor in the strain difference since EB and P can alter the number and function of 5-HT1 
and 5-HT2 receptors (Sumner et al., 1999; Moses et al., 2000; Mize et al., 2003) and 
progesterone has been reported to reduce the lordosis inhibiting effects of fluoxetine 
(Guptarak et al., 2010).  However, we do not believe this to be the case since strain 
differences remained even when rats were administered the identical hormonal treatment.  
Moreover, differential exogenous hormonal treatment cannot account for the comparable 
strain difference in naturally cycling females. 
 Studies with ketanserin were initiated because of the apparent inconsistency 
between the strain difference in response to fluoxetine and the 5-HT1A receptor agonist.  
5-HT2A/2C receptor agonists can protect against the lordosis-inhibiting effects of 5-HT1A 
receptor activation (Maswood et al., 1996) so it was hypothesized that, following 
treatment with fluoxetine, 5-HT2A/2C receptors might be providing greater protection in 
Sprague-Dawley than in Fischer females.  Since such strain differences did not exist,  
5-HT2A/2C receptors are unlikely to explain the apparent inconsistency.  Therefore, the 
most viable explanation for the directional reversal in response to fluoxetine and a 5-
HT1A receptor appears to reside in a strain difference in levels of 5-HT at neuronal sites 
important for lordosis behavior. 
 Fischer rats have been reported to have more SERT mRNA in the dorsal raphe 
nucleus (DRN) than Sprague-Dawley rats (Burnet et al., 1994).  If there is greater SERT 
activity in the dorsal raphe of Fischer females, fluoxetine should produce a smaller 
increase in extracellular 5-HT in that brain area.  With such a smaller increase in 
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extracellular 5-HT, there would be a correspondingly smaller increase in activation of 
DRN inhibitory 5-HT1A autoreceptors.  As a consequence, fluoxetine’s reduction in the 
firing of DRN 5-HT neurons would be smaller in Fischer than in Sprague-Dawley rats.  
This would result in more extracellular 5-HT after fluoxetine in Fischer females than in 
Sprague-Dawley females in areas of the brain such as the mediobasal hypothalamus that 
are important for sexual behavior.  Such an explanation would allow for Fischer rats to be 
more sensitive to fluoxetine and also less sensitive to a 5-HT1A receptor agonist. 
 Although the current studies appear to rule out 5-HT2A/2C receptors as a 
contributor to the strain difference in response to fluoxetine, it is important to note that 
ketanserin has both 5-HT2A and 5-HT2C receptor blocking activity (Kristiansen and Dahl, 
1996) so additional studies with more selective antagonists are required before definitely 
ruling out a strain difference in these receptors.  In addition, ketanserin binds to both 
alpha - adrenergic and histamine receptors (Hoyer et al., 1987; Marin et al., 1990; 
Marwood, 1994; Wouters et al., 1985) which may have (a) influenced the response to 
ketanserin and/or (b) counteracted potential strain differences in 5-HT2A/2C receptor 
functioning.   
 If, indeed, 5-HT2 receptors were responsible for the strain difference in response 
to fluoxetine, then a combination of fluoxetine and ketanserin should have produced a 
strain difference in lordosis inhibition.  An additive effect between the two drugs was 
anticipated since fluoxetine has 5-HT2 receptor antagonist properties (Pälvimäki et al., 
2005).   Based on fluoxetine’s 5-HT2 receptor antagonist activity and prior studies that 
ketanserin amplified effects of SSRIs (Boothman et al., 2006), it was surprising that the 
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combination of fluoxetine and ketanserin did not have an additive effect.  Boothman et al. 
reported that the route of drug administration may be important when SSRIs and a 5-
HT2C antagonist were being used together (Boothman et al., 2006).  For example, they 
found greater augmentation when the SSRI was combined with local infusion of a 5-HT2 
antagonist.  Hence, it is possible that the failure to observe such augmentation in the 
current study was the result of the systemic application of both drugs.  In addition, 5-HT2 
receptor antagonists may not be as effective in combination with fluoxetine as with other 
SSRIs (Boothman et al., 2006).     
 Therefore, the collective data are most consistent with the following model. 
1. Fischer rats have more SERT in the DRN than do Sprague-Dawley so that 
fluoxetine’s increase in extracellular 5-HT in the DRN would be smaller in 
Fischer. 
2. 5-HT 1A autoreceptors on serotonergic neurons inhibit firing of the 
serotonergic neurons in the DRN. 
3. An increase in the extracellular 5-HT would increase activation of 5-HT1A 
autoreceptors on the serotonergic neurons in the DRN. 
4. This would reduce the amount of extracellular 5-HT in the VMN. 
5. Fluoxetine blocks SERT and if there are more SERT present, it would require 
more fluoxetine to saturate SERT. 
6. Fischer females would, therefore, have less activation of 5-HT1A autoreceptors 
following fluoxetine. 
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7. Fischer rats would then have more 5-HT released in the VMN and therefore 
show greater lordosis inhibition than Sprague-Dawley rats. 
8. Fischer rats would then have more 5-HT released in the VMN and therefore 
show greater lordosis inhibition than Sprague-Dawley. 
 In summary, activation of 5-HT1A receptors is an important factor for lordosis 
behavior.  The strain differences in SERT in the DRN could explain the importance of  
5-HT1A receptor activation and the sequence of events that can result in the decline in 
lordosis in Fischer rats.  The observed strain differences to fluoxetine in intact, naturally 
cycling rats and ovariectomized rats and the effects of 8-OH-DPAT on lordosis in the two 
strains and the absence of such strain differences in response to ketanserin implicate 
strongly the role of 5-HT1A receptors in fluoxetine-mediated lordosis inhibition.  
Ketanserin and fluoxetine were not additive in their effect on lordosis; their combination 
reflected primarily the lordosis inhibition with ketanserin alone.  The modest strain 
differences in response to 5-HT2 receptor antagonism cannot explain earlier finding of 
strain difference to fluoxetine.  However, future studies with a more selective antagonist 
might be worthwhile.  The individual difference in occurrence of SSRI-induced sexual 
dysfunction varies within the human female population.  One possible candidate for these 
differences in sensitivity may be SERT, which plays a major role in reuptake of  
5-HT and for which genetic polymorphisms exist in the human population.  This could be 
one direction to explore that may help to understand the individual differences in sexual 
dysfunction in women who are treated with SSRIs. 
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response to acute treatment with Prozac®, data collection from experiments, data analysis using 
statistical tools such as SPSS.  Manuscript preparation, poster preparation and presentation at 
national conferences and at Texas Woman’s University symposia, trained undergraduate students in 
laboratory.   
 
Teaching experience 
 
Graduate Teaching Assistant, Department of Biology, Texas Woman’s University, Denton, Texas 
(2007-2009) 
 
Instructed undergraduate microbiology laboratory, administered exams, quizzes, graded exams and 
reported class progress to supervisor.  Worked towards the objective of training students to work 
independently and as a team and directed them to accomplish the course objectives. 
 
Instructor, Department of Microbiology, St. Francis Degree College for Women, Hyderabad, 
Andhra Pradesh, INDIA (2006-2007) 
 
Instructed lecture and laboratory classes for undergraduate Microbiology course, demonstrated and 
trained students to conduct experiments, helped students to work towards the course goals and 
reported class progress to supervisor. 
 
Instructor, Department of Microbiology, NMR College, Hyderabad, Andhra Pradesh, INDIA (2005-
2006) 
Instructed lecture and laboratory classes for undergraduate Microbiology course, prepared and set up 
laboratory prior to conducting experiments, demonstrated and trained students to conduct 
experiments, helped students to work towards the course goals and reported class progress to 
supervisor. 
 
Research Projects 
 
• Effect of 5-HT2 receptor antagonist, ketanserin, on sexual behavior in Fischer and Sprague-
Dawley strains 
• Strain differences in response to fluoxetine induced sexual dysfunction 
• RU486, a progesterone receptor antagonist, reduces progesterone’s protection against the effects 
of mild restraint 
• Medroxyprogesterone, a synthetic progesterone, prevents lordosis inhibition after mild restraint 
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• Effect of finasteride on progesterone-induced resistance to restraint stress 
• 8-OH-DPAT modulation of fluoxetine-induced anorexia in ovariectomized rats with and without 
hormone priming 
 
Research Publications 
 
Miryala,C.S.J., Hiegel,C. and Uphouse,L. 2013. Comparison of female Fischer and Sprague-
Dawley rats in the response to ketanserin.  Submitted to Pharmacol. Biochem. Behav. 
 
Miryala, C.S.J., Hiegel, C. and Uphouse, L. 2012. Sprague-Dawley and Fischer female rats differ in 
acute effects of fluoxetine on sexual behavior.  J. Sex. Med. doi: 10.1111/j.1743-6109.2012.02981.x 
Adams, S., Miryala, C.S.J., Hassell, J., Uphouse, L. 2012. RU486 blocks effects of allopregnanolone 
on the response to restraint stress. Pharmacol. Biochem. Behav.\., doi:10.1016/j.pbb.2012.09.024 
Miryala, C.S.J., Hassell, J, Adams, S., Hiegel, C., Uzor, N. and Uphouse, L. 2011.  Mechanisms 
responsible for progesterone’s protection against lordosis inhibiting effects of restraint. II. Role of 
Progesterone metabolites.  Horm. Behav., 60: 219-224. doi:10.1016/j.yhbeh.2011.05.006 
Hassell, J., Miryala, C.S.J., Hiegel, C. and Uphouse, L. 2011. Mechanisms responsible for 
progesterone’s protection against lordosis inhibiting effects of restraint. 1. Role of Progesterone. 
Horm. Behav. 60:226-232. doi:10.1016/j.yhbeh.2011.05.005 
Miryala, C.S.J., N., Maswood and Uphouse, L.  2011. Fluoxetine prevents 8-OH-DPAT-induced 
hyperphagia in Fischer inbred rats.  Pharmacol. Biochem.  Behavior, 98:311-31.5 
doi:10.1016/j.pbb.2011.01.014 
Research Presentations 
 
• Annual Student Creative Arts and Research Symposium at Texas Woman’s University, 
Denton, Texas. 
 
2013:   Chandra Suma Johnson Miryala, Cindy Hiegel and Lynda Uphouse. Do Fischer and  
            Sprague-Dawley females differ in their response to 5-HT2 receptor antagonist? 
2012:  Chandra Suma Johnson Miryala, Cindy Hiegel, Sarah Adams, and Lynda Uphouse.     
 Fischer and Sprague-Dawley female rats show different sensitivities to serotonin 2 receptor 
blockages        
2012:  Aminata Diaby, Cindy Hiegel, Chandra Suma Johnson Miryala and Lynda Uphouse. 
 Estradiol benzoate, alone, is sufficient for induction of lordosis behavior                       
2012:   Sarah Adams, James Hassell, Chandra Suma Johnson Miryala, Cindy Hiegel, and Lynda 
Uphouse. RU486 blocks protective effects of allopregnanolone on the response to restrain               
2012:  Sarah Ndedi, Chandra Suma Johnson Miryala and Lynda Uphouse.  Fluoxetine reduces 
the female’s active investigation of a male incentive 
2011:  Chandra Suma Johnson Miryala, Cindy Hiegel, James Hassell, and Lynda Uphouse. Strain 
differences in antidepressant-induced sexual dysfunction 
Chandra Suma Miryala 
 
4 
 
2010:   C.S. Miryala, J. Hassell, C. Hiegel, L. Uphouse. Finasteride fails to prevent  progesterone’s  
            protection against mild restraint                   
2009: Miryala, C.S.J., N., Maswood and Uphouse, L. Does 8-OH-DPAT attenuate fluoxetine     
         induced anorexia.                                            
• Federation of North Texas Area Universities, Graduate Student Research Symposium 
 
2013:   Chandra Suma Johnson Miryala, Cindy Hiegel and Lynda Uphouse. Do Fischer and  
            Sprague-Dawley females differ in their response to 5-HT2 receptor antagonist? 
2012:  Chandra Suma Johnson Miryala, Cindy Hiegel, Sarah Adams, and Lynda Uphouse.     
 Fischer and Sprague-Dawley female rats show different sensitivities to serotonin 2 receptor 
blockages        
2011:  Chandra Suma Johnson Miryala, Cindy Hiegel, James Hassell, and Lynda Uphouse. 
 Strain differences in antidepressant-induced sexual dysfunction                   
2010: C.S. Miryala, J. Hassell, C. Hiegel, L. Uphouse. Finasteride fails to prevent  progesterone’s 
protection against mild restraint 
 
• Society for Neuroscience Presentations 
 
2011:  C.S.J Miryala, James Hassell, Cindy Hiegel, and Lynda Uphouse.  Female Fischer and  
 Sprague-Dawley rats differ in fluoxetine-induced sexual dysfunction, annual Meeting of 
 the Society for Neuroscience, Washington D.C., November 2011 
2010:  L.L. Uphouse, J.E. Hassell, C.S.J. Miryala and C. Hiegel. Redundant mechanisms 
 involved in progesterone’s protection against restraint-induced inhibition of lordosis 
 behavior, Annual Meeting of the Society for Neuroscience, San Diego, November 2010 
 
Professional Membership  
 
Member of Society for Neurosciences 
 
Membership in Honor Societies 
 
Phi Kappa Phi 
 
Scholarships 
 
• Former Student Association scholarship for the period 2011-2012 
• TWU General Scholarship for the period 2010-2011 
 
Awards 
 
2011, 2012 and 2013: Chancellor’s Student Research Scholar award  
 
2013:  First prize for poster presentation titled “Do Fischer and  
           Sprague-Dawley females differ in their response to 5-HT2 receptor antagonist?” 
           at the Federation of North Texas Area Universities Graduate Student Research Symposium 
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TWU Services 
 
2008-2011 Assisted with the conference ‘Expanding Your Horizons’ by American Association of 
       University Women 
2009        Judge at TWU Science Fair 
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